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Summary 
Breast cancer is one of the most common cancers worldwide and the most common 
cancers in women. As in other types of cancer, breast cancer is a multi-factorial 
disease, consisting of various internal and external factors influencing the 
development and progression of the disease. Hypoxia and estrogen signalling have 
been established to be involved in the development of breast cancer. 
Hypoxia plays a crucial role in tumour development and metastasis. The key 
regulator in cellular hypoxic adaptation is hypoxia-inducible factor (HIF), which 
consists of the constitutively expressed -subunit and the oxygen-sensitive -subunit. 
HIF- can be classified into three different isoforms: HIF-1, HIF-2 and HIF-3, 
among which HIF-2 is one of the less well characterised isoforms. Although HIF-2 
has long been reported, the functional consequences and regulation of HIF-2 are 
not well understood. Wnt-1-inducible signalling protein 2 (WISP-2) is one of the few 
known genes to be selectively induced by HIF-2. Clinically, patients expressing both 
WISP-2 and AREG have been reported to possess significant overall survival. Four 
hypoxia response elements (HREs) were discovered within the WISP-2 promoter, in 
which two HREs were necessary for WISP-2 regulation by HIF-2. Moreover, the two 
active HREs are located within microsatellite (MS) regions which have been 
established to play an essential role in tumour progression. A negative correlation 
between WISP-2 expression and tumour macrophage numbers was observed, 
supporting the better prognosis of patients expressing WISP-2, as lower macrophage 
infiltration means lower cancer aggressiveness. Furthermore, proliferation, 
anchorage-independent colony formation, and scratch recovery assays suggest the 
reduction in the tumourigenic properties of MCF-7 breast cancer cells, in line with the 
tumour-suppressor like characteristic of WISP-2 and its regulation by HIF-2. 
Besides hypoxia, the involvement of estrogen (E2) in the development and 
progression of breast cancer is well established. In this study, treatment of E2 on 
estrogen receptor (ER)-positive breast cancer cell lines resulted in HIF-2 mRNA 
and protein downregulation. The involvement of ER was confirmed with the absence 
of HIF-2 downregulation upon treatment of E2 on ER-negative breast cancer cell 
lines. Moreover, the role of ER in the downregulation was further established by 
utilising both pharmacological and siRNA approaches. An investigation of 690 
samples from breast cancer patients revealed the association of HIF-2 tumour 
levels with a better prognosis in the triple-positive patients, which was validated with 
less pronounced HIF-2 downregulation on a triple-positive breast cancer cell line, 
BT474. To explore the potential molecular mechanism, trichostatin A (TSA), a histone 
deacetylate (HDAC) inhibitor, was added together with E2. The blunting of HIF-2 
downregulation in the presence of TSA indicated the transcriptional origin of HIF-2 
downregulation. In silico analysis revealed the presence of four bound estrogen 
response elements (EREs) within the first intron of EPAS1, in which one ERE was 
activated upon treatment with E2. 
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In conclusion, this thesis reports functional consequences of HIF-2 in human breast 
cancer by its regulation of WISP-2. Furthermore, the novel regulation of HIF-2 by 
estrogen signalling was described, which might partially explain the association of 
high HIF-2 in triple-positive breast cancer patients with better prognosis. 
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Zusammenfassung 
Weltweit ist Brustkrebs eine der häufigsten Krebserkrangkungen und die häufigste 
bei Frauen. Wie bei anderen Typen von Krebs, ist Brustkrebs eine vielfältige 
Krankheit, bestehend aus inneren und ausseren Faktoren, die die Entwicklung und 
das Fortschreiten der Krankheit beeinflussen. Aus der molekularen Perspektive sind 
die beiden Faktoren Hypoxie und der Östrogen-Signalweg, welche an der 
Entwicklung des Brustkrebs beteiligt sind, gut untersucht. 
Hypoxie ist wichtig für die Entwicklung des Tumors und die Metastase. Der 
Hauptregulator in der Anpassung an zelluläre Hypoxie ist der Hypoxie-induzierbare 
Faktor (HIF), der aus einer konstitutiv exprimierten -Untereinheit und einer 
Sauerstoff-sensitiven -Untereinheit besteht. Diese tritt in drei unterschiedlichen 
Isoformen auf. Darunter stellt HIF-2 eine der weniger erforschten Untereinheiten 
dar. Insbesondere die HIF-2 Regulierung und deren funktionelle Auswirkungen sind 
bisher kaum untersucht worden. Das Wnt-1-induzierbare Signal Protein 2 (WISP-2) 
ist eines der wenigen Gene, welches durch HIF-2 selektiv induziert wird. Patienten 
mit einer erhöhten WISP-2 und Amphiregulin (AREG) Expression haben klinisch 
gesehen eine höhere Überlebensrate. Innerhalb des WISP-2 Promotors wurden vier 
Hypoxie responsive Elemente (HREs) entdeckt, von denen zwei für die HIF-2 
abhängige WISP-2 Regulierung zuständig sind. Die beiden HREs liegen in einer 
Mikrosatellitenregion (MS), welche bei der Tumorentwicklung eine wichtige Rolle 
spielt. Des weiteren konnte eine negative Korrelation zwischen der WISP-2 
Expression und der Anzahl an Makrophagen Tumor-assoziation festgestellt werden. 
Eine geringere Infiltration der Makrophagen geht mit einem weniger aggressiven 
Krankheitsverlauf einher. Dies unterstützt die Beobachtung, dass Patienten mit einer 
erhöhten WISP-2 Expression eine bessere Prognose erhalten. Ausserdem zeigten 
die Zellproliferation, Ankergrund-unabhängige Kolonie formierung, und „Scratch“ 
Versuche eine Senkung der Tumor-Eigenschaften durch WISP-2 in MCF-7 
Brustkrebs Zellen. Dies bestätigt die Tumorsuppressorcharakteristik des WISP-2 und 
seine Regulierung durch HIF-2. 
Ausser Hypoxie ist die Rolle des Östrogens (E2) in der Entwicklung und dem 
Fortschreiten des Brustkrebs schon gut bekannt. Experimente mit Östrogenrezeptor 
(ER)-positiven Brustkrebszelllinien, welche mit E2 behandelt wurden, wiesen auf eine 
reduzierte Menge an HIF-2 mRNS und Protein hin. Die Mitwirkung des ER konnte 
mit der Abwesenheit der HIF-2 Herunterregulierung nach der E2 Behandlung von 
ER-negativen Brustkrebszellen bestätigt werden. Zusätzlich konnte der Effekt von 
ER auf die HIF-2 Herunterregulierung pharmakologisch und durch siRNS 
Methoden belegt werden. Die Analyse von 690 Brustkrebspatientenproben wies auf 
eine Assozation des HIF-2 Tumorgehalts und einer besseren Prognose der dreifach 
Rezeptor-positiven Patienten hin. Mit Hilfe der dreifach Rezeptor-positiven 
Brustkrebszelllinie BT474 konnte die reduzierte Herunterregulierung von HIF-2 
nach E2 Behandlung ebenfalls bestätigt werden. Um den potenziellen molekularen 
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Mechanismus zu untersuchen, der diesem Effekt zu Grunde liegt, wurden die Zellen 
mit Trichostatin A (TSA), einem Histon Deacetylase (HDAC) Inhibitor, und E2 
behandelt. Die Abnahme der HIF-2 Herunterregulierung in der Anwesenheit von 
TSA deutet darauf hin, dass die Herunterregulierung auf transkriptioneller Ebene 
stattfindet. Eine in silico Analyse zeigte die Anwesenheit von vier Östrogen 
responsiven Elementen (EREs) im ersten Intron von Endothelial PAS domain-
containing protein 1 (EPAS1), wovon ein ERE durch die Hinzugabe von E2 aktiviert 
wurde. 
Zusammenfassend wurden im Rahmen dieser Dissertation die funktionellen 
Zusammenhänge von WISP-2 und dessen Regulierung durch HIF-2 bei der 
Brustkrebsentwicklung untersucht. Zudem wurde die neu entdeckte E2-abhängige 
Regulierung von HIF-2 und die Assoziation zwischen dem Gehalt von HIF-2 in 
dreifach Rezeptor-positiven Brustkrebspatienten und einer besseren Prognose 
beschrieben. 
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1. Breast Cancer 
1.1 Introduction 
Breast cancer is the most common cancer in women worldwide and the second most 
common cancer overall, with approximately 1.7 million new cases diagnosed in 
20121,2. This number represents 12% of all new cancer cases and 25% of all cancers 
in women1,2. In the United States, breast cancer incidence rates have increased 
constantly at a rate of 1% per year since 19403. This increase is not limited to 
developed countries as the incidence is likewise on the rise in many developing 
countries, including Asian countries that have previously been shown to have a low 
risk of breast cancer, such as Japan and Singapore4. In contrast to the incidence 
rates, the breast cancer mortality rates have plateaued and in some countries have 
started to decline5,6. The decline of the mortality rates has been attributed to 
improvements in the screening procedures6. Similarly, advances in breast cancer 
treatment have generated significant but modest survival benefits, contributing to 
lower mortality rates6. 
Epidemiological observations showed that daughters of women from low-incidence 
countries who migrate to high-incidence countries acquire the breast cancer risk of 
the host country, suggesting that environmental and/or behavioural factors play a 
more significant role in the development of breast cancer than genetic factors7. In 
fact, genetic factors are responsible for at most 5-10% of the breast cancer cases8. 
Various population-based studies have implicated multiple factors involved in breast 
cancer development. These factors include genetic susceptibility and family history, 
endogenous steroid hormone levels, age of menarche and menopause, parity, 
lactation, physical attributes and activity, social and dietary habits, and exposure to 
environmental pollution9. However, it is still uncertain whether these factors cause 
breast cancer. As such, the fundamental cause of breast cancer development 
remains unknown. 
 
1.2 Breast development 
The breast is a bilateral organ overlying the chest (pectoral) muscles and is made of 
specialised tissue that produces milk (glandular tissue) and fatty tissue, which 
determine the size of the breast10. The glandular tissue of female breast is made up 
of two different structures: the lobes and the ducts, with each breast consisting of 
approximately 15 to 20 lobes (Figure 1.1)10-12. Each lobe is made up of numerous 
smaller sections termed lobules, which in turn consist of tiny bulbs which produce 
milk13,14. The three structures are then linked by thin tubular ducts. 
In female, breast progressively undergoes changes in association with infantile 
growth, puberty, pregnancy, lactation, and post-menopausal regression15,16. Human 
breast development is a life-long process which starts during embryonic life, followed 
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by the major growth spurt with lobular development during puberty and finally with the 
completion of the development and differentiation by the end of the first full-term 
pregnancy17. Case control studies have shown an inverse relationship between the 
risk of breast cancer and early parity, especially that the risk of breast cancer 
increases with the age at which a woman experiences full-term pregnancy18. The 
protective factor in these observations appears to be the duration between the age of 
menarche and the age of first full-term pregnancy19. The actual mechanism behind 
the protective properties of first full-term pregnancy on breast cancer development is 
yet unknown, but the fact that pregnancy induces breast differentiation led to the 
speculation that the state of breast differentiation is important for breast cancer 
development. 
 
Figure 1.1 Representation of female breast anatomy. Female breast consists of a network of lobes 
and ducts embedded within fatty tissue and attached to the chest (pectoral) muscles. The nipple and 
areola are located outside of the breast. (For the National Cancer Institute © 2011 Teresa Winslow 
LLC, U.S. Govt. has certain rights) 
1.2.1 Prenatal, perinatal and postnatal development  
The mammary gland tissue originates from a single epithelial ectodermal bud and 
begins during early foetal life, approximately 4 weeks after conception20. After birth, 
mammary gland develops at the same pace as the general growth of the body21. The 
first major development of breast occurs during puberty, with the growth of glandular 
tissue and the surrounding stroma20. Furthermore, the ducts grow and divide to form 
the terminal end buds (TEBs), which together with the terminal ducts (TD) and the 
proliferating ductules form the first identifiable lobular structure termed the lobule type 
1 (Lobule 1) or terminal ductal lobular unit (TDLU)22. The breast tissue in a non-
pregnant female with continuous cycles of sex steroid exposure consists of three 
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identifiable structures, the aforementioned Lobule 1, the more developed lobule type 
2 (Lobule 2) and the further developed Lobule 322. 
As the female undergoes sexual maturation the percentages of the three lobular 
types change23. During sexual maturation, Lobule 1 undertakes gradual sprouting of 
new ductules and eventually formed a denser lobular structure termed the Lobule 223. 
The breast reaches its maximum development during pregnancy; active proliferation 
of the ductal tree occurs, rapidly increasing the number of ductules generated and 
results in the conversion of Lobule 2 into Lobule 3 (Figure 1.2)15. The breast is then 
fully differentiated during lactation with the formation of Lobule 4 before undergoing 
post-lactational involution15 
 
Figure 1.2 Representation of lobular structures in the breast. The diagram shows the lobular 
structures of non-lactating female breast. TEB: terminal end buds, Lob 1: lobule type 1, Lob 2: lobule 
type 2, Lob 3: lobule type 3. (Adapted from Russo and Russo, 200415) 
The influence of parity can be observed from the development and the distribution of 
the different types of lobules within the breast23. In nulliparous female, the 
percentage of Lobule 1 remains constant, with modest increase in the percentage of 
Lobule 2 during the early reproductive years and sharply decreasing after the age of 
23, and complete absence of Lobule 323. This observation of the difference in the 
composition of lobules between parous and nulliparous females suggests that 
several Lobule 1 might have progressed into Lobule 2, but no Lobule 2 have 
progressed to Lobule 323. In combination with the fact that the more differentiated 
lobules possess lower proliferation activities; this might be a possible explanation for 
the higher risk of breast cancer in nulliparous women. 
1.2.2 Hormonal regulation of breast development 
The breast is a hormone-sensitive organ whose development is influenced by a 
myriad of hormones and growth factors, affecting cell proliferation, cell differentiation 
and apoptosis24-26. Among the multiple hormones influencing the development of 
breast, estrogens are considered to be the major hormones by promoting the 
proliferation of both normal and neoplastic breast epithelium24,27. Estrogens act 
TEB 
Lob 1 
Lob 2 
Lob 3 
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locally on the mammary gland and stimulate DNA synthesis, cell proliferation and bud 
formation28,29. In a classical model of estrogen actions, the binding of estrogens to 
their receptors (ERα and ERβ) results in the formation of a homodimer with the 
corresponding other ligand-activated ER, followed by nuclear translocation and 
transactivation of downstream target genes containing estrogen response elements 
(EREs)30. Another steroidal hormone with important, albeit controversial implications 
in mammary gland development is progesterone31-33 
The role of progesterone in breast development is controversial due to the fact that 
progesterone receptor (PgR) is a known downstream target of estrogen signalling, 
and hence the difficulties in differentiating the action of estrogen signalling and 
progesterone signalling in breast development. There have been multiple reports 
describing the role of estrogen as a stimulant for cell proliferation, however, the 
breast epithelium of sexually mature and normally cycling female does not exhibit 
maximal proliferative activity during the follicular phase of the menstrual cycle, when 
estrogen is at its peak levels (200 pg/ml serum compared to progesterone < 1 ng/ml 
serum)34,35. Instead, the breast epithelium reaches its maximal proliferation during the 
luteal phase, when progesterone reaches its peak levels of 10-20 ng/ml serum, while 
estrogen levels drop to 2- or 3-fold lower than during the follicular phase, suggesting 
the possible cooperation between estrogen and progesterone signalling in breast 
development35 
Besides the responsiveness of breast epithelium to circulating hormones, the degree 
of differentiation of the mammary parenchyma also plays a role in regulating the 
proliferation of breast epithelium in both rodents and humans17,36. In human, the 
highest level of cell proliferation occurs in the non-differentiated cells of Lobule 137. 
Interestingly, the highly proliferating cells within the non-differentiated Lobule 1 also 
possess the highest amounts of ERα and PgR38. Furthermore, the content of ERα 
and PgR together with the proliferation rate is decreasing progressively in the more 
differentiated Lobule 2, Lobule 3, and Lobule 4, suggesting the role of both estrogen 
and progesterone signalling in breast development38. As breast cancer development 
is often associated with increasing proliferation, these observations provide additional 
rationale for the higher risks of breast cancer in nulliparous female compared to 
parous female, due to the higher proportion of non-differentiated Lobule 1 in 
nulliparous female and the higher content of ERα and PgR38. 
  
1.3 The pathogenesis of breast cancer 
Breast development, which occurs during the period of female sexual maturation 
between menarche and first full term pregnancy, represents a period of high 
susceptibility for the initiation of breast cancer. The classification of the lobular 
structures of breast into the non-differentiated Lobule 1 to the fully differentiated 
Lobule 4 has assisted in describing the site of origin of breast cancer23. Observations 
of breast development have identified the TDLU as the site of origin of the ductal 
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carcinoma, which is highly associated with the abundance of Lobule 139. 
Furthermore, other lobular structures have been identified as sites of origin for 
specific types of breast carcinoma: Lobule 2 is the site of origin for lobular carcinoma, 
Lobule 4 originates hyperplastic lobules, cysts, fibroadenomas, and adenomas, and 
Lobule 4 give rise to lactating adenoma40. 
From observing breast development, a concept emerged postulating that breast 
architecture is an important factor in determining the susceptibility of the human 
breast to cancer23,41. The breast composition between nulliparous and parous 
females differ regarding the presence of the non-differentiated Lobule 1 and the more 
differentiated Lobule 2 and Lobule 3, with nulliparous female exhibiting higher 
proportion of Lobule 1 and vice versa for parous female23. Together these 
observations suggest that breast cancer originates from the non-differentiated 
terminal structures of the mammary gland23. Furthermore, the Lobule 1, which is the 
site of the most common carcinoma, the ductal carcinoma, proliferates at its maximal 
rate during early adulthood, coincides with the highest susceptibility of the breast to 
carcinogenesis, providing a rationale in identifying genes controlling breast 
development for breast cancer prevention42. 
 
1.4 Genomic changes in breast cancer development 
Breast cancer, as other types of cancer, is a genetic disease and it has been 
reported that genetic factors contribute to approximately 5-10% of breast cancer 
cases8. Two types of genetic alterations might contribute to the initiation and 
development of breast cancer: microsatellite instability (MSI) and loss of 
heterozygosity (LOH).  
1.4.1 MSI and LOH in breast cancer development 
Microsatellites are repeated sequences (approximately 5-50 repeats) of DNA with 
lengths ranging from 2-5 base pairs. Microsatellites are presence in multiple locations 
in the human genome and are known for their diversity within the population43. MSI is 
a hypermutable phenotype and reflects the presence of defective DNA replication 
processes and the loss of DNA mismatch repair mechanism43. The MSI phenotype is 
common in some colon, gastric, pancreatic and endometrial cancer44-46. It is detected 
in 15% of colorectal cancer; however its occurrence in breast cancer has been so far 
inconsistently reported44,47,48. Several observations have supported the involvement 
of MSI in breast cancer initiation. MSI has been reported to be positively correlated 
with the progression of human breast carcinoma in situ into invasive carcinoma49. In 
vitro studies have also shown an association between the presence of MSI and the 
immortalisation and progressive transformation of non-cancerous human breast 
epithelial cells (HBECs)50. 
LOH is a chromosomal event, in which an individual possesses only one functionally 
active allele. LOH increases the chance of cancer development in an individual and it 
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is the most common genomic alterations observed in human cancers51. LOH is a 
molecular representation of aneuploidy, which is a common feature of all cancer52. 
This type of genetic alteration might contribute to cancer development via deletion of 
tumour suppressor genes and dysregulation of general gene expression, which leads 
to abnormal growth control53-55. 
1.4.2 Genes involved in breast cancer development 
Normal HBECs have limited proliferative activity and a common characteristic of all 
cultured HBECs is their limited life span in vitro56. Under standard culture medium 
maintenance, HBECs undergo approximately 30-40 times population doublings 
before terminal differentiation and senescence, comparable to adult human 
fibroblasts56. From the in vitro perspective, immortalisation of cells represents an 
initial step in the development of breast carcinoma, which is comparable to the ductal 
hyperplasia or the pre-neoplastic stage in vivo. As such, investigating differential 
gene expression between non-immortalised HBECs and immortalised HBECs might 
illuminate genes important in the initiation of breast carcinoma. Two particular genes 
have been reported to be differentially expressed between non-immortalised HBECs 
and the immortalised HBEC cell line MCF-10F57,58. The two genes are ferritin H chain 
and S100p57,58. 
The ferritin H chain is an important component of cellular iron transport and its 
expression is associated with intake of iron59. Intake of iron and its associated 
transport proteins have been reported to play a significant role in cell proliferation by 
influencing DNA synthesis via its activity on the enzyme ribonucleotide reductase60. 
The increase in proliferation might assist in the development of breast carcinoma61. 
Furthermore, increase in intracellular iron content might increase the free radical 
reactions leading to oxidative damage and mutation of DNA62. Another possible 
mechanism in which ferritin H chain might contribute to breast cancer is the role of 
ferritin as modulator of immune response by modulating the maturation of B and T 
lymphocytes and providing growth advantage for breast cancer cells63,64. 
The S100P calcium-binding protein is highly expressed in breast cancer compared to 
the adjacent normal tissues65. S100P is a member of the so-called S100 calcium-
binding proteins, which play an important role in maintaining intracellular calcium 
concentration66. S100P has been reported to be a prognostic factor for hepatocellular 
carcinoma, colorectal cancer, gastric cancer and breast cancer67-71. The 
dysregulation of intracellular calcium maintenance with the overexpression S100P 
might result in dysfunctional assembly of microtubules, which in turn leads to an 
increase in motility and invasive property of cells72. Additionally, calcium can act as 
secondary messenger, which activates the immediate early genes responsible for 
inducing resting cells to re-enter cell cycle and in turn affects the proliferation of 
cells73. 
Another gene, which when mutated is almost always associated with carcinogenesis, 
is p5374. The p53 protein is a nuclear phosphoprotein possessing anti-proliferative, 
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cell cycle-regulatory, and apoptotic inducing properties75-77. As such, it has been 
identified as tumour suppressor gene. The p53 gene is often mutated in breast 
carcinoma, associated with an increase in genomic instability and further mutations of 
proto-oncogenes into oncogenes, such as ras, c-myc, and mdm78-81. 
 
1.5 Treatment of breast cancer 
Currently there are five standard treatments of breast cancer patients: surgery, 
chemotherapy, radiotherapy, endocrine therapy and targeted therapy. 
1.5.1 Surgery 
Surgery has been the procedure of choice for the treatment of breast cancer for 
centuries, with the first publication of a radical mastectomy in 189482. The basic 
principle underlying surgery as a method of treatment is removal of cancerous or 
potentially affected breast tissue. This will convey maximum protection and remedy 
from breast cancer. Three types of surgery are currently available: breast-conserving 
mastectomy, total mastectomy, and modified radical mastectomy83. 
As the name suggests, breast-conserving mastectomy is a type of mastectomy in 
which cancer and some normal tissues surrounding it are removed except for the 
breast itself. It is also often termed as lumpectomy, partial mastectomy, segmental 
mastectomy, quadrantectomy, or breast-sparing surgery. Total mastectomy or simple 
mastectomy is the total removal of the breast with cancer. And lastly, modified radical 
mastectomy is a type of surgery, in which the whole breast with cancer, the lymph 
nodes under the arm, the lining of the chest muscles and part of the chest wall 
muscles are removed. 
1.5.2 Chemotherapy 
Chemotherapy is a type of cancer treatment in which one or more chemotherapeutic 
agents are introduced to the patients to stop the growth of cancer cells, either by 
killing the cells or preventing cell division. This treatment works as cancer cells 
proliferate faster than normal cells. Two types of chemotherapy regimen are currently 
available: anthracycline-based regimens and methotrexate-based regimens84. The 
anti-tumour activity of anthracycline is based on the ability of the antibiotics to 
intercalate between DNA and RNA base pairs and hence blocking DNA replication 
and transcription85. Furthermore, anthracycline also inhibits topoisomerase II 
enzyme, which is required for DNA transcription and replication86. Meanwhile, 
methotrexate acts by inhibiting folic acid reductase, an enzyme required for DNA 
synthesis and cellular replication87. The anthracycline-based regimens have been 
reported to be clinically more effective than methotrexate-based regimens88. 
However, the anthracycline-based regimens have more adverse side effects, with 
association between anthracycline with heart failure reported in older patients with 
history of cardiac diseases89. 
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Chemotherapy may also be given to patients before mastectomy in a procedure 
termed neo-adjuvant therapy90. The rationale behind this pre-treatment is to reduce 
the size of the tumour and hence reducing the amount of tissue that needs to be 
removed during mastectomy. 
1.5.3 Radiotherapy 
In radiotherapy, ionising radiation is applied to control or kill malignant cells. Ionising 
radiation works by inducing DNA damage and subsequently cellular death. 
Cancerous cells proliferate at a faster rate compared to normal cells and hence the 
higher likelihood of the ionising radiation targeting cancer cells. 
Radiotherapy is applied as either a curative therapy for localised tumours or as part 
of adjuvant therapy to prevent recurrence of tumour. Generally, radiotherapy is 
offered for women with recurrent cancer who had no prior radiation. The treatment 
protocol consists of whole-breast radiation for 6 – 6,5 weeks83. Radiotherapy is often 
used in conjunction with chemotherapy in a combination therapy called chemo-
radiotherapy91,92. 
1.5.4 Endocrine therapy 
The importance of hormones in carcinogenesis has long been known since 
prolonged exposure to female sex hormones has been associated with the 
development and progression of breast, vaginal, hepatic and cervical carcinomas93-
95. Furthermore, a vast majority of breast cancers are initially hormone-dependent 
and especially estrogen-dependent96. These provide a rationale for endocrine 
therapy, a cancer treatment in which hormone actions are blocked to prevent cancer 
cells from proliferating. 
Tamoxifen is currently the first-line treatment for all stages of breast cancer as 
recommended by the World Health Organisation (WHO)97. Tamoxifen is a 
triphenylethylene anti-estrogen which is often given to patients with early, surgically 
removable, localised breast cancer and patients with metastatic breast cancer98. 
However, patients using tamoxifen possess higher risk of developing endometrial 
cancer99. As second-line treatment, aromatase inhibitors are used for the treatment 
of advanced breast cancer. Aromatase inhibitors, such as fadrozole, vorozole and 
liarozole, are often given to post-menopausal female with ER-positive breast 
cancer100. Unlike tamoxifen, which blocks the activation of ER, aromatase inhibitors 
inhibit the enzyme aromatase which is involved in the conversion of androgens into 
estrogens. However, aromatase inhibitors should not be given to pre-menopausal 
females, since aromatase inhibitors activate the hypothalamic-pituitary-adrenal axis 
with the consequence of increase androgen production101. 
1.5.5 Targeted therapy 
Targeted therapy can technically be considered as “chemotherapy” as it is also a 
type of treatment in which drugs or other substances are introduced to kill cancer 
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cells. However unlike traditional chemotherapy drugs which target rapidly dividing 
cells by interfering with general cell division processes, such as DNA replication and 
microtubule assembly, targeted therapy drugs identify and interfere with specific 
molecules critical for tumour progression without affecting normal cells, normally 
using specific antibodies against the molecules involved. The specificity of targeted 
therapy drugs results in the same or even more effective treatment compared to 
radiotherapy and chemotherapy, and additionally with less harmful side effects to 
healthy cells. 
Currently there are two main types of targeted therapies: monoclonal antibody 
therapy and small-molecule therapy102. The introduction of trastuzumab (anti-
Herceptin monoclonal antibodies), which blocks the effects of the growth factor 
HER2, has heralded the arrival of targeted therapy as one of several treatment 
options for breast cancer patients103. Other currently available targeted therapy drugs 
for breast cancer treatment include Pertuzumab and Ado-trastuzumab emtansine, 
which is an antibody-drug conjugate used to treat HER2-positive breast cancer that 
has metastasised104. 
Besides antibody-based drugs, targeting specific proteins unique to cancer cells, 
small-molecule drugs are also used as targeted therapy drugs. Small-molecule drugs 
target proteins required for cell proliferation, such as tyrosine kinases (lapatinib) and 
cyclin-dependent kinases (palbociclib); or DNA repair and apoptosis, such as poly 
(ADP-ribose) polymerase (PARP)105-107. 
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2. Hypoxia 
2.1 Introduction 
Oxygen is essential for the maintenance of life of all eukaryotes, including unicellular 
organisms, plants and animals. During evolution, early organisms developed the 
requisite tools, such as chlorophyll pigment which eventually developed into 
photosynthetic chloroplast, to convert carbon dioxide (CO2) and water (H2O) into 
glucose (C6H12O6) and oxygen (O2)108. The spread of these photosynthetic 
organisms brought about the rise of O2 concentration in the atmosphere, which 
eventually led to the appropriate environment for metazoan evolution108. 
The importance of oxygen for the maintenance of life is mainly due to the role it plays 
as final electron acceptor in the mitochondrial respiratory chain108. By accepting 
electrons, oxygen allows the oxidative phosphorylation process to proceed. This 
subsequently leads to a more efficient generation of adenosine triphosphate (ATP), 
the currency for intracellular energy transfer; with 30 molecules of ATP per glucose 
compared to 2 molecules of ATP per glucose in anaerobic glycolysis109. Under 
normoxia, the relatively high ATP/ADP ratio is maintained by the availability of 
oxygen and the continuous generation of ATP via oxidative phosphorylation, hence 
the dependence of cells on oxygen109. 
Hypoxia is defined as an imbalance between oxygen supply and consumption 
leading to a reduction in oxygen to a level insufficient to maintain normal cellular 
function110. In multicellular organisms, such as Homo sapiens, hypoxia occurs in both 
physiological and patho-physiological conditions110. Hypoxia has been reported to 
play essential roles in embryonic development, cancer, atherosclerosis, and ischemic 
disease111-114. Due to the essentiality of oxygen in human physiology, a mechanism 
must exist in order to sense the level of oxygen and to induce adaptation processes 
to cope with changes in oxygen level. 
 
2.2 Adaptation to hypoxia 
The absolute requirement of oxygen in the survival of most living organisms 
necessitates adaptation processes in response to changes of environmental oxygen 
level. Fundamentally, adaptation to hypoxia can be classified based on the time of 
responds: acute responses (occurring over a time period of seconds to minutes) and 
chronic responses (occurring over a longer time period of several hours to days). 
2.2.1 Acute responses to hypoxia 
The deficiency of oxygen is a major factor in the pathogenesis of numerous diseases, 
which might lead to the death of the organism. In multicellular organisms, particularly 
in mammals, responses to acute hypoxia require rapid systemic respiratory and local 
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cardiovascular regulations in order to ensure sufficient oxygen delivery to critical 
organs such as the brain and the heart. 
The changes in oxygen partial pressure are also sensed by glomus cells within the 
aortic and carotid bodies115. Glomus cells (type I) are peripheral chemoreceptors, 
which can sense a decrease in oxygen partial pressure (pO2) and increase in carbon 
dioxide partial pressure (pCO2), a parameter tightly associated with decreased blood 
pH115. The activation of the cardiorespiratory centre of the medulla leads to an acute 
and reversible increase in ventilation in order to transport more oxygen to the 
lungs116,117. This acute increase in ventilation is followed by a ventilator decline and 
then a slow increase in ventilation which occurs during the acclimatisation 
period116,117. The decrease in pO2 induces increases in heart rate and cardiac output 
in order to deliver more oxygen to the peripheral tissues115. Subsequent responses 
include systemic arterial vasodilation and pulmonary vasoconstriction, particularly in 
the coronary and cerebral vessels115. In summary, a decrease in oxygen level 
induces physiological changes to compensate for the lower oxygen level by activating 
processes that increase the availability of oxygen. 
Cellular responses of type I glomus cells to acute hypoxia depend on the activity of 
excitable cells with oxygen-dependent ion channels, which modulate the excitability 
and secretory activity of the cells upon changes in pO2118. The excitation of cells by 
hypoxia relies on the open probability of membrane K+ channels which is decreased 
by low pO2119. In essence, low pO2 induces the closure of K+ channels, which 
subsequently leads to membrane depolarisation, opening of voltage-gated 
Ca2+channels, influx of Ca2+, release of transmitters, including ATP, dopamine and 
acetylcholine, into the synaptic cleft and activation of afferent nerve fibres119,120. 
2.2.2 Chronic responses to hypoxia 
Contrary to acute responses, chronic exposure to hypoxia results mainly in the 
induction of gene expression, which facilitates the switch of ATP generation from 
oxygen-dependent oxidative phosphorylation to oxygen-independent glycolysis, 
increases the oxygen-carrying capacity of blood, and increases vascularisation for 
better transport of oxygen to tissues121. 
One fundamental way in which cells adapt to chronic exposure of hypoxia is to 
increase the usage of glucose via non-oxygen dependent mechanisms122. In most 
cells, hypoxia induces the expression of glucose transporters and glycolytic 
enzymes123. Glucose transporter 1 (GLUT1) is a transport protein which facilitates the 
transport of glucose across the plasma membrane124. Other enzymes, whose 
expression is induced by hypoxia, include aldolase A, hexokinase, glyceraldehyde-3-
phosphate dehydrogenase, lactate dehydrogenase, phosphofructokinase, pyruvate 
kinase, and triphosphate isomerase125-130. 
Additionally, O2 partial pressure of blood also induces the expression of 
erythropoietin (EPO)131. EPO is a glycoprotein hormone which acts as a cytokine for 
erythrocyte (red blood cells) precursors in the bone marrow132. As such, EPO is the 
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primary factor in erythropoiesis, a process in which erythrocytes are produced132. The 
sites of EPO production are in peritubular fibroblast-like cells of adult kidney and in 
hepatocytes of foetal and adult liver, which sense changes in tissue pO2 and respond 
by inducing the transcription of EPO132. EPO is subsequently released into the blood 
stream and stimulates proliferation and differentiation and prevents apoptosis of the 
erythrocyte precursors in the bone marrow. Erythrocytes are the major blood oxygen 
transporters due to the content of haemoglobin within their cytoplasm. As such, 
induction of erythrocyte production restores the oxygen-carrying capacity of the 
blood. 
Finally, angiogenesis is regulated by changes in oxygen tension both in physiological 
development and in adaptation to local hypoxia133. Several hypoxically-induced 
cytokines are required for angiogenesis: vascular endothelial growth factor (VEGF), 
angiopoietin-1, angiopoietin-2, and Tie2134-137. The most thoroughly studied 
angiogenic factor, VEGF, is expressed in nearly all tissues and cells, but its receptor 
is only expressed in endothelial cells, further supporting its function in inducing 
angiogenesis. 
 
2.3 The canonical hypoxia signalling pathway 
2.3.1 The hypoxia-inducible factor (HIF) 
Hypoxia-inducible factors (HIFs) are heterodimeric complexes consisting of two 
subunits: an oxygen-labile α-subunit and a constitutively expressed β-subunit. HIF 
proteins are members of the bHLH-PAS (basic helix loop helix-Per/ARNT/Sim) family 
of TFs138. The oxygen-regulated α-subunits are classified into three different 
isoforms: HIF-1α, HIF-2α, and HIF-3α. All of the three HIF-α subunits are 
homologous to each other, but while HIF-1α is ubiquitously expressed, HIF-2α and 
HIF-3α possess a more limited tissue expression profile139. Interestingly, HIF-1α and 
HIF-2α are not redundant and have specific roles in tumourigenesis, with publications 
reporting a specific down-regulation of HIF-1α and increased expression of HIF-2α 
under continuous hypoxia140,141. The N-terminus of HIF-α contains bHLH and PAS 
domains, while the C-terminus of the molecule contains two transactivation domains 
and one oxygen-dependent degradation (ODD) domain except for HIF-3 (Figure 
2.1). 
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Figure 2.1 Schematic representation of HIF-α and HIF-β structures. The diagram shows the 
compositions of HIF subunits: HIF-1, 2, 3α and HIF-β. NLS: nuclear localisation signal, bHLH: basic 
helix loop helix domain, PAS: Per/ARNT/Sim motif, ODDD: oxygen-dependent degradation domain, N-
TAD: N-terminal transactivation domain, C-TAD: C-terminal transactivation domain. 
The N-terminal bHLH mediates DNA binding and specificity. Both the bHLH and PAS 
domains mediate heterodimerisation with HIF-β. The ODD domain contains two 
distinct proline residues (P402 and P564 in HIF-1α), which are the sites for PHD-
dependent hydroxylation, thus regulating HIF-α protein stability142. HIF-1α and HIF-
2α possess both an N-terminal transactivation domain (N-TAD) and a C-terminal 
transactivation domain (C-TAD), while HIF-3α possess only one transactivation 
domain143,144. Interestingly, the C-TAD also contains an asparagine residue, which is 
the site of hydroxylation by factor inhibiting HIF (FIH), thus regulating the 
transcriptional activity of the CAD. Additionally, an inhibitory domain (ID) is located 
between the two transactivation domains which is necessary for normoxic repression 
of the CAD. 
2.3.2 HIF prolyl-4-hydroxylases (PHDs) 
The major regulators of HIF-α are HIF-prolyl-4-hydroxylases (PHDs), which target 
HIF-α subunits for proteasomal degradation under normoxia through hydroxylation. 
PHDs, or HIF prolyl hydroxylases (HPHs), are evolutionarily conserved oxygen 
sensors that use oxygen and 2-oxoglutarate (2-OG) as co-substrates, and iron and 
ascorbate as co-factors145. Three homologs of PHDs, PHD1, 2 and 3, are 
differentially expressed in mammals: PHD2 is generally the dominant isoform in 
tissues, with the exception of the testis, in which PHD1 is the most abundant, the 
heart and skeletal muscle, in which PHD3 expression predominates146,147. PHDs 
have a common structural architecture, with a well conserved C-terminal hydroxylase 
domain and a more variable N-terminal domain, whose functions are poorly 
characterised148. While PHD1 and PHD2 contain 407 and 426 amino-acid residues 
respectively, PHD3 is much shorter (239 amino-acid residues) with a much shorter 
and more divergent N-terminal sequence (Figure 2.2)149. 
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Figure 2.2 Protein sequence alignment of PHD1, PHD2 and PHD3. PHD1, PHD2 and PHD3 
protein sequences are aligned using constraint-based multiple alignment tool (COBALT) from PubMed 
Central-National Centre for Biotechnology. Red colour represents conserved regions. Numbers in 
brackets represent the numbers of amino acids within the gaps. 
As the most dominant form of PHDs, it is no surprise that prenatal deficiency of 
PHD2 results in embryonic lethality at E12.5 due to placental and heart defects150.  
Somatic or postnatal ablation of PHD2 results in increased EPO and angiogenesis 
via HIF stabilisation, and hence in polycythaemia and congestive heart failure151. 
Meanwhile, PHD1-deficient mice are viable with improved hypoxia tolerance in 
skeletal muscle and liver attributable to reprogramming of anaerobic 
metabolism152,153. Similarly PHD3-knockout mice are viable but with abnormal 
sympathoadrenal development, demonstrated by a reduction in adrenal medullary 
secretory capacity, hypo-functional sympathoadrenal system and decreased blood 
pressure154. Fascinatingly, combined genetic ablation of PHD1 and PHD2 leads to 
increase in haematocrit due to increased EPO expression in the liver of adult mice146. 
2.3.3 HIF pathway 
The essential step in the chronic responses to hypoxia is the stabilisation and 
activation of the HIFs. In the canonical pVHL/PHD/HIF pathway, PHD enzymes 
hydroxylate two distinct prolyl residues within an ODD domain of HIF-α under 
normoxia. Hydroxylation of these residues increases the binding affinity of HIF-α to 
the von Hippel-Lindau (VHL) tumour suppressor protein. VHL acts as a recognition 
tag, which recruits an ubiquitin E2 ligase complex. This then results in poly-
ubiquitination and proteasome-dependent degradation of HIF-α. Under hypoxia, the 
hydroxylation is reduced and hence the stabilisation of HIF-α increased, allowing it to 
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form a heterodimer with the constitutively expressed HIF-β. The HIF heterodimer 
transcriptionally activates a large number of genes involved in the adaptation process 
to low pO2 (Figure 2.3)155. 
 
Figure 2.3 Schematic of canonical HIF-signalling pathways. The presence of oxygen resulting in 
hydroxylation of HIF-α by PHDs and subsequent recognition by pVHL, ubiquitination and proteasomal 
degradation of the α-subunit. In hypoxia, the hydroxylation does not occur, resulting in stabilisation of 
HIF-α, dimerization with HIF-β and recognition of the hypoxia-response element (HRE), followed by 
transcription of target genes. 
Despite of the similarity between HIF-1α and HIF-2α, both factors are expressed in 
distinct cell types139,156. HIF-1α expression can be observed in all nucleated cells of 
metazoan species, while HIF-2α expression is more restricted to specific cell types, 
such as renal interstitial cells and hepatocytes156. Interestingly stabilisation of HIF-1α 
and HIF-2α under hypoxia displays different kinetics140,141. Continuous exposure of a 
variety of human cancer cell lines to hypoxia results in a down-regulation of HIF-1α 
whereas HIF-2α protein levels increase140,141. This suggests the adaptive activation 
of HIF depending on exposure to acute or chronic hypoxia and hence regulation of 
different downstream target genes from HIF-1α or HIF-2α. 
 
2.4 Hypoxia and breast cancer 
Hypoxia plays a significant role in tumour development and metastasis157,158. Hypoxia 
is observed in more than half of all cancers and is an adverse prognostic marker in 
various types of human cancer and is independent of other prognostic factors such 
as tumour stage, histological grade and lymph node status159. The ultimate cause of 
mortality in breast cancer patients is the propagation of breast cancer cells from the 
primary tumour site to distant organs in a process termed metastasis158. The 
increased cell proliferation and decreased cell death are hallmarks of breast cancer 
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cells160. An increase in breast cancer cell numbers leads to increased oxygen 
consumption, hence decreased in O2 availability (hypoxia). Hypoxia in turn leads to 
the activation of HIFs and subsequently drives further breast cancer pathogenesis. 
The progression of metastasis in breast cancer is a multistep process. The process 
includes the acquisition of aggressive and invasive phenotypes by the cancer cells, 
enhancement in the ability to intravasate from the site of origin to the lymphatic or 
blood vessels and extravasate from the lymphatic or blood vessels into the metastatic 
site, and finally to ability to revert back to epithelial phenotype for clonal expansion 
and colonisation of the metastatic site. Moreover, the HIF signalling pathway induces 
angiogenesis, which is essential for the growth of primary tumour and the 
progression of metastasis133. An example of gene that is hypoxically-regulated is 
Wnt-1-induced signalling protein-2 (WISP-2)161. 
2.4.1. HIF-2α-mediated regulation of WISP-2 
Previously, the dependence of 34 known HIF target genes on HIF-1 and HIF-2 was 
analysed by our laboratory using quantitative PCR in MCF-7 cells exposed to hypoxia 
for 4-72 hours and was grouped by K-means clustering into four distinct groups with 
8-10 set members (Figure 2.4)161. Unsurprisingly, the majority of genes investigated 
were predominantly depending on HIF-1, such as glycolytic enzymes and genes 
involved in metabolic adaptation to low oxygen availability, with only a few genes 
showing activation by HIF-2. One of the genes selectively activated by HIF-2 is 
WISP-2, a secreted protein member of the connective tissue growth factor/cysteine-
rich 61/ nephroblastoma overexpressed (CCN) family which has previously been 
reported to be hypoxically induced by cooperation between HIF-2α and the ETS 
oncogene family member ETS-like gene (ELK-1)162. 
 
Figure 2.4 HIF target gene clustering based on their distinct hypoxic expression profile. 34 
known target genes of HIF were analysed by RT-qPCR and was grouped into four distinct groups 
(adapted from161). 
Chapter 2: Hypoxia 
17 
 
WISP-2, also called CCN5, is a secreted protein member of CCN family and is 
approximately 29 kDa in size162. CCN family proteins consist of 6 members (CCN1-6) 
which are matricellular proteins with conserved modular domains involved in 
angiogenesis, cell proliferation, tumourigenesis and wound healing163-166. Structurally, 
except for WISP-2, CCN family proteins contain four conserved domains: insulin-like 
growth factor binding proteins (IGF-BP), von Willebrand factor-C (VWC), 
thrombospondin-1 (TSP-1), and cysteine knot (CT) domains (Figure 2.5)167. The lack 
of the CT domain in WISP-2 indicates a functional difference compared with other 
members of the CCN family. In fact, the CT domain has been reported to be a 
proliferation domain, suggesting a role of WISP-2 in mediating proliferative properties 
of cells168. 
 
Figure 2.5 Structure of CCN family members. CCN family proteins are composed of 4 motifs 
separated by a hinge region which is susceptible to proteolytic cleavage. IGFBP: insulin-like growth 
factor binding protein, VWC: von Willebrand factor-C, TSP1: thrombospondin-1, CT: cysteine knot. 
(Adapted from 167) 
Several publications have asserted the important role WISP-2 in the progression of 
cancer, including breast cancer, colorectal cancer and pancreatic cancer169-171. In 
breast cancer, WISP-2 is expressed in a biphasic manner, in which it is undetected in 
normal HMECs, highly expressed in non-invasive breast cancer cells (MCF-7 and T-
47D) and again undetected in highly invasive breast cancer cells (MDA-MB-231 and 
MDA-MB-468)172. The loss of WISP-2 in MCF-7 induces estrogen-independent 
growth and promotes EMT. Re-expression of WISP-2 in highly invasive MDA-MB-231 
cells results in reduction of proliferation, which is consistent with a more invasive 
phenotype173. 
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3. Estrogen Signalling 
3.1 Introduction 
In 1896, British physician George Beatson reported the relationship between cancer 
of the breast and ovarian function, in which the removal of ovaries caused reduction 
in circulating estrogen, resulted in remission of advanced breast cancer174. His 
publication heralds the introduction of the significance of hormones in the 
carcinogenic process174. More than 50 years after Beatson’s observation, Rous and 
Kidd in 1941 proposed the multifactorial concept of tumourigenesis and the existence 
of latent cancer cells based on the studies of skin cancer induction by carcinogens175. 
Further studies led to the generalisation that carcinogenesis is a two-step process, 
involving initiation and promotion. 
It was not until 1975, however, that hormones are acknowledged to be carcinogen-
like, not only by a genotoxic mechanism, but also by influencing the rate of cell 
proliferation and thereby increasing the potential for spontaneous mutations176. 
Furthermore, Jacob Furth proposed that unrepaired copying mistakes during DNA 
replication could generate cells carrying new karyotypes, which are potential 
ancestors of novel clones predisposed to become malignant tumours176. Furth’s 
description of the carcinogen-like potential of hormones is further supported by 
MacMahon and colleagues’ suggestion that estrogens, generally, and estradiol, 
specifically, could play a role in human breast cancer carcinogenesis177. 
With the discovery and characterisation of BRCA1 and BRCA2, the importance of 
inherited traits in breast cancer causation comes to the spotlight178,179. Surprisingly 
however, mutations in these genes contribute little to nothing to the causation of 
sporadic breast cancer180. Moreover, mutations in the TP53 tumour suppressor gene 
contribute to increased risk of breast cancer development in certain families, but not 
generally to the risk of sporadic breast cancer181. These observations lead to the 
current view that under the majority of circumstances, breast epithelial cell does not 
possess a germline mutation in tumour suppressor genes181. Circulating steroid 
hormones (e.g. ovarian estradiol and to a lesser extent progesterone) drive 
proliferation of breast epithelium28,182. Increasing breast cell proliferation in turn 
increases the risk of a DNA copying mistake that is not repaired by the DNA repair 
machineries, which then facilitates expression of genetic errors by loss of 
heterogeneity that eventually leads to a malignant phenotype176. 
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3.2 Steroid hormones 
In the human body, generation of steroid hormones occurs de novo by biosynthetic 
pathways in specific endocrine glands (the adrenals and ovaries in women and the 
adrenals and testes in men) (Figure 3.1)183. Additionally, steroid hormones can be 
produced in peripheral tissues from circulating precursors that are generated by the 
endocrine glands. Important peripheral tissues include the liver, kidney, breast, 
prostate, brain and skin.   
 
Figure 3.1 Biosynthesis of steroid hormones from cholesterol. Cholesterol serves as the 
precursor to the generation of progesterone, aldosterone, cortisone, estrogen and testosterone 
(Adapted from 35). 
The first step in the biosynthesis of steroid hormones in the endocrine glands is the 
conversion of cholesterol to pregnenolone184. The conversion reaction occurs in the 
mitochondrion and is catalysed by the cholesterol side-chain cleavage cytochrome P-
450 (P450scc) enzyme together with auxiliary electron-transferring proteins184. 
Following the conversion of cholesterol to pregnenolone by the mitochondrial side-
chain cleavage system, pregnenolone can be converted to either progesterone or 
17α-hydroxypregnenolone, which is catalysed by 3β-hydroxysteroid dehydrogenase 
(3β-HSD)9. 
Pregnenolone and progesterone can undergo hydroxylation at carbon 17, and 
subsequent cleavage of the side chain at carbon 17 catalysed by P450c17, 
generating dehydroepiandrosterone (DHEA) and androstenedione respectively185. 5-
Androsterone-3β, 17β-diol and testosterone are converted from DHEA and 
androstenedione, respectively, through the action of 17β-hydroxysteroid 
dehydrogenase (17β-HSD)186. Lastly, testosterone is converted into estradiol through 
the action of a complex microsomal aromatase cytochrome P-450 (P450arom) in 
reactions called aromatisation9. 
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3.3 Estrogen 
Estrogens are the primary female sex hormones, which have been shown to regulate 
diverse physiological processes in both reproductive and non-reproductive tissues, 
such as in the mammary, cardiovascular, hepatic and osseous tissues187-189. In 
human, estrogen consists of 17β-estradiol (E2), the most abundant and potent 
estrogen, and its less potent metabolites estrone (E1) and estriol (E3) (Figure 3.2)190. 
E2 is the major estrogen during the pre-menopausal period of a female’s life, while 
E1 plays a larger role after menopause, when it is generated from adrenal DHEA in 
adipose tissue191. E3, which is converted from E1 through 16α-hydroxylation, is 
generated by the placenta during pregnancy191. 
 
Figure 3.2 Structures of estrogens. Three major forms of estrogens are present in females: 17β-
estrone (E1), 17β-estradiol (E2) and 17β-estriol (E3)190.  
 
 
 
 
 
 
 
Chapter 3: Estrogen Signalling 
21 
 
3.3.1 Biosynthesis of estrogen 
In pre-menopausal women, the major sites of estrogens synthesis are the corpus 
leteum of the ovaries and the placenta, with a small but substantial amount of 
estrogens also generated by non-gonadal organs, such as the liver, heart, skin and 
brain191,192. The estrogens produced in the ovaries of pre-menopausal women are 
directly released into the bloodstream, where they act on their corresponding 
receptors in the target organs. In non-reproductive women, such as pre-puberty 
females and post-menopausal females, non-gonadal organs are the major sources of 
estrogens191. The non-gonadal organs include kidney, adipose tissue, skin and 
brain191,192. However, unlike the bloodstream-bound estrogens produced in the 
ovaries, non-gonadal organ-synthesised estrogens act mostly within the vicinity of the 
site of synthesis in a paracrine or intracrine manner192. Importantly, estrogens are 
also synthesised in male testes and are essential in the regulation of normal male 
gonadal development and spermatogenesis193.   
In a healthy reproductive age woman, estrogen synthesis in the ovaries occurs during 
the process of folliculogenesis, the maturation of the ovarian follicle (Figure 3.3a)194. 
Two major cell types within the ovaries are involved in the synthesis of estrogen in a 
cooperative manner: the Thecal cells and Granulosa cells35. The complementarity of 
these two cells can be observed by the sharing of burdens, in which the thecal cells 
provide both structural support to the follicle and being the sole producer of 
androgens from progesterones, which are required for estrogen synthesis in the 
neighbouring granulosa cells194. In folliculogenesis, the activation of the primordial 
follicle induces the formation of secondary follicle and simultaneously signals the 
stroma surrounding the follicle to recruit thecal cells194. The recruited thecal cells 
surround the follicle and start to differentiate. Upon the release of luteinising hormone 
(LH) from the pituitary, androgens are synthesised by the necessary enzymes 
located within the mitochondria and endoplasmic reticulum of the thecal cells194. 
Subsequently, the synthesised androgens are transported to the granulosa cells, 
where they are converted into E1 and E2 by P450arom (Figure 3.3b)185. 
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A 
 
B 
 
Figure 3.3 Biosynthesis of estrogen in the ovaries. (A) The stages of follicle development during 
folliculogenesis (Adapted from 35). (B) Estrogen synthesis in the ovaries depends on the cooperation 
between thecal and granulosa cells (adapted from 194). 
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3.3.2 Estrogen receptors 
The effects of estrogens are mediated primarily via their receptors, estrogen 
receptors (ERs), which include the classical receptors such as ERα and ERβ, and 
membrane-bound receptors such as G protein-coupled estrogen receptor 1 (GPER) 
and ER-X195-197. Although, both types of ER are activated by estrogen and facilitate 
downstream effects, the nuclear ERs mediate transcriptional changes in a time 
course of hours or days, while the membrane-bound ERs trigger a rapid intracellular 
signalling cascade. ERα and ERβ are members of the nuclear receptor (NR) 
superfamily that function as ligand-inducible transcription factors. ERα and ERβ are 
encoded by different genes located on different chromosomes, ESR1 on 
chromosome 2 and ESR2 on chromosome 14 respectively. Both ERα and ERβ 
possess similar architecture, consisting of six modular domains that are functionally 
distinct: domain A-F (Figure 3.4)198. 
 
Figure 3.4 Structures of ERα and ERβ. ER consists of ERα and ERβ, which possess striking 
similarities (96% sequence homology) in their DNA binding domain (DBD). However they are 
functionally distinct, due to differences in the activation domains (AF-1 and AF-2)198. 
The A/B domain of ERs is highly variable (approximately 15% sequence similarity) 
and contains a ligand-independent trans-activation function (AF-1)198. The C 
functional domain contains a highly conserved DNA binding domain (DBD) which 
targets ER to their cognate binding sites containing estrogen response elements 
(EREs, 5’-GGTCANNNTGACC-3’)199. Nuclear localisation sequence (NLS) and 
dimerisation region are located within the C functional domain. The D domain or the 
hinge domain is the most variable region among NRs and represents a linker 
between the DBD and the ligand binding domain (LBD) and it also plays a role in the 
stabilisation of the LBD198. The LBD or the E domain specifically binds with 
estrogens198. Moreover, this domain also possesses dimerisation, co-factor 
interaction, heat shock protein (hsp) binding, nuclear localisation regions and the 
ligand-dependent activation function (AF-2). The AF-2 has been reported to be 
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implicated in transcriptional regulation via the recruitment of the co-regulators200,201. 
Finally, the carboxyl-terminal F domain is highly divergent and is involved in 
transcriptional modulation and receptor dimerisation202,203.  
3.3.3 Estrogen signalling pathways 
Estrogen signalling pathways can be broadly classified into four different 
mechanisms based on the dependence on ER, the initiation sites, and the ligand 
requirement191. Although most estrogen-mediated signalling pathways are ER-
dependent, ER-independent signalling pathways occur. ER-dependent pathways can 
further be classified based on whether the initiation occurs in the nucleus or plasma 
membrane. Furthermore, an ER-independent signalling pathway has been reported 
recently in the improvement of vascular function by estrogen204.  
The classical mechanism is an ER-dependent, nuclear-initiated estrogen signalling 
pathway (Figure 3.5). Estrogen binding triggers the dissociation of hsp90 from the 
ER, followed by dimerisation and nuclear translocation of the ligand-receptor 
complex. The activated ERs can form either homodimers or heterodimers, which 
regulate distinct sets of E2-responsive genes205. Mutation analysis indicated that the 
dimerisation interface required in the formation of heterodimerisation is very similar to 
that required for homodimerisation206. Additionally, the ER/ER heterodimers are 
capable of interacting with co-regulators206. These observations suggest that the 
presence and the ratio of ER and ER within different cell types determine the 
regulation of E2-responsive genes. Inside the nucleus, the estrogen/ER dimeric 
complex recruits the transcriptional machinery and other co-factors and binds to the 
EREs of the target genes and induces or represses target gene transcription. 
Besides binding directly to the EREs, activated ERs can form an indirect association 
with the DNA by interacting with other transcription factors, such as stimulating 
protein-1 (SP-1) and activator protein-1 (AP-1)207,208. 
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Figure 3.5 Schematic representation of the classical ER-dependent nuclear-initiated estrogen 
signalling pathway. The binding of estrogen to ERα/β induces dimerization of the receptors and 
translocation to the nucleus, where the activated receptor dimer interacts with other transcription 
factors to induce transcription of downstream target genes.  
An alternative to the nuclear-initiated pathway is the ER-dependent, membrane-
initiated estrogen signalling. Unlike the longer time it takes for the nuclear-initiated 
pathway, the membrane-initiated estrogen signalling is usually acting rapidly either 
via crosstalk with other membrane receptors or via activation of a variety of 
cytoplasmic signalling cascades (Figure 3.6)190. ERα and ERβ have been reported to 
mediate downstream signalling through the activation of a variety of protein kinase 
cascades, such as MAPK/ERK and PI3K/AKT pathways190. In addition to membrane-
bound ERα and ERβ, rapid signalling by estrogen is also mediated by GPER and 
ER-X197,209. GPER is an estrogen-induced membrane receptor and is located in the 
plasma membrane, Golgi apparatus, and endoplasmic reticulum210. GPER has been 
reported to mediate rapid estrogen signalling via its association with the 
phosphorylation of ERK1/2, activation of PI3K and PLC, regulation of intracellular 
cAMP and Ca2+ levels209,211-215. ER-X, a high-affinity, saturable membrane-bound ER, 
is expressed in the brain, uterus, and lungs, and has been reported to be functionally 
distinct from ERα and ERβ197. 
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Figure 3.6 ER-dependent, membrane-initiated estrogen signalling pathway. The membrane-
initiated estrogen signalling is usually rapid and involves a variety of protein kinase cascades.  
Recently more studies have shown estrogen signalling independent of the activation 
of ERs216-218. The phenolic A ring of estrogen possesses an intrinsic anti-oxidant 
property, which provides estrogen with the ability to exert anti-oxidant effects and 
suppress oxidative stress by hydrogen peroxide, superoxide anions and other pro-
oxidants in an ER-independent manner219-221. Furthermore knockout experiments 
have shown that E2 treatment can promote breast cancer development in mice 
lacking ERα and ERβ expression, suggesting ER-independent effects on tumour 
formation222. Moreover, further studies have reported the presence of ligand-
independent estrogen signalling pathways216-218. In this pathway, a variety of factors, 
such as the neurotransmitter dopamine, the growth factors epithelial growth factor 
(EGF) and insulin-like growth factor (IGF) and the protein kinases PKC, PKA, MAPK, 
PI3K, can activate ERs mostly via phosphorylation216,217,223-226.  
 
3.4 Hypoxia and estrogen signalling in breast cancer   
Besides regulating numerous aspects of human physiology, estrogens have also 
been reported to influence diverse pathophysiological processes, such as 
carcinogenesis, cardiovascular diseases, osteoporosis and Alzheimer’s disease227-
230. Prolonged exposure to E2 is one of the major factors in breast carcinogenesis231. 
ERs, especially ERα, exert a major role in the development of breast cancer; 
therefore providing the rationale behind the use of tamoxifen, an ER antagonist, as a 
primary treatment option for most breast cancer patients99. The importance of ERα in 
breast cancer development is further supported by the overexpression of ERα in 
approximately 70% of breast cancer diagnosed96,231. Another hallmark of cancer cells 
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in general and breast cancer cells specifically is their ability to adapt to various 
changes in oxygen supply. Oxygen partial pressures differ substantially in solid 
tumours, ranging from normal oxygen partial pressure (normoxia) condition near the 
circulation to complete oxygen deprivation (anoxia) in the core of the tumour. One of 
a few factors promoting the survival of breast cancer cells depends on the 
adaptability of the cells to hypoxia, which is mediated by HIFs. With the significance 
of both hypoxia and estrogen in breast cancer development, surprisingly little 
attention has been paid on the interaction between these two contrasting signalling 
pathways. 
3.4.1 Estrogen-dependent regulation of HIF-1α   
E2 has been reported to attenuate the hypoxic induction of HIF-1α and subsequent 
attenuation in EPO expression in Hep3B cells via ER-dependent protein 
regulation232. Interestingly, exposure of MCF-7 breast cancer cell lines to E2 results 
in rapid induction of HIF-1α protein synthesis, with expression of HIF-1α under 
normoxia observed by immunoblot experiments233. The increase in HIF-1α protein 
synthesis occurs due to the activation of PI3K/AKT pathway by the E2-ERα complex, 
leading to the phosphorylation and activation of mammalian target of rapamycin 
(mTOR) protein233. Subsequently, mTOR stimulates protein translation, including 
HIF-1α protein translation, by phosphorylation of p70 S6 kinase and 4EB-P233.  The 
opposing results of HIF-1 regulation by estrogen might be due to the different 
factors expressed in the two different cell lines.    
Contrary to HIF-1α activation by ERα, ERβ has been reported to play an opposing 
role234. ERβ has been predicted to play an essential role in prevention of breast 
cancer development and metastasis, with reports indicating the inhibitory effects of 
ERβ in proliferative activity in vitro235,236. Furthermore, ectopic overexpression of ERβ 
significantly reduced tumour growth in severe combined immunodeficiency (SCID) 
mice235. Consistent with the opposite effects of ERβ to ERα, transcriptional activity of 
HIF-1α is inhibited by ERβ, which is mediated via ubiquitin-dependent degradation of 
HIF-β with subsequent reduction of HIF-1α/HIF-β complex and hence reduction in 
DNA binding and thus transcriptional activity237.     
3.4.2 Estrogen-dependent regulation of HIF-2α   
The potential involvement of E2 in regulating HIF-1α has been previously reported as 
described above. Nonetheless, there is currently no report regarding the effects of E2 
exposure on the regulation of HIF-2α. HIF-2α has been reported to be a positive 
prognostic factor in breast cancer, which has been further confirmed with the 
designation of HIF-2α in a list of genes associated with favourable outcome based on 
studies with different cohorts of breast cancer patients161,230. Combined with various 
observations of HIF-1α regulation by E2, we aimed for the investigation of the 
potential connection between hypoxia and estrogen signalling in breast cancer, and 
in particular to the estrogen signalling-dependent regulation of HIF-2α. 
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4. Aims of the thesis 
The aims of the thesis are to: 
1. Examine the role of HIF-2 in breast tumourigenesis by elucidating the 
regulation of WISP-2 by HIF-2 and to explore the roles of both HIF-2 and 
WISP-2 in the aggressiveness of breast cancer, and hence their contribution in 
overall survival in breast cancer patients.  
2. Investigate the potential regulation of HIF-2 by estrogen signalling in breast 
cancer cell lines.  
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5.1 Abstract  
Hypoxia and the hypoxia-inducible factor (HIF) signalling pathway trigger the 
expression of several genes involved in cancer progression and therapy resistance. 
Transcriptionally active HIF-1 and HIF-2 regulate overlapping sets of target genes 
and only few HIF-2 specific target genes are known so far. Here we investigated the 
oxygen-regulated expression of the Wnt-1 induced signalling protein 2 (WISP-2) 
which has been reported to attenuate breast cancer progression. WISP-2 was 
hypoxically induced in low-invasive luminal-like breast cancer cell lines on both 
mRNA and protein levels, mainly in a HIF-2 dependent manner. HIF-2 driven 
regulation of the WISP-2 promoter in breast cancer cells is almost entirely mediated 
by two, phylogenetically only partially conserved, functional hypoxia response 
elements (HREs) located in a microsatellite region upstream of the transcriptional 
start site. High WISP-2 tumour levels were associated with increased HIF-2, 
decreased tumour macrophage density and a better prognosis. Silencing WISP-2 
increased the anchorage-independent colony formation and recovery from scratches 
in confluent cell layers of normally low-invasive MCF-7 cancer cells. Interestingly, 
these changes in cancer cell aggressiveness could be phenocopied by HIF-2 
silencing, suggesting that the direct HIF-2 mediated transcriptional induction of 
WISP-2 gene expression might at least partially explain the association of high HIF-
2 tumour levels with prolonged overall survival of breast cancer patients. 
Keywords: invasion, metastasis, motility, oxygen, tumour, transcriptional regulation 
Chapter 5: Manuscript I. Hypoxia. 2014; 2:23-33 
44 
 
5.2 Introduction 
Temporally and spatially variable tissue hypoxia is characteristic of solid tumors.1 
Hypoxia-inducible factors (HIFs) allow cancer cells to adapt to microenvironmental 
tissue hypoxia, affecting all aspects of tumour progression, including metabolism, 
proliferation, inflammation, angiogenesis and metastasis.2-5 Importantly, HIFs are 
also involved in cancer therapy resistance and overall survival correlates with HIF 
levels in a cancer type-specific manner.6-8 Transcriptionally active HIFs are 
heterodimers usually composed of a constitutively expressed  subunit and either a 
HIF-1 or a HIF-2 subunit, whose stability and activity is regulated by oxygen-
dependent protein hydroxylation.9, 10 Despite their high structural similarity and 
identical DNA sequence recognition, several studies identified specific roles of HIF-1 
and HIF-2 in tumorigenesis.11-13 We and others previously showed in a variety of 
cancer cell lines that HIF-1 protein levels decreased under prolonged hypoxia while 
HIF-2 levels increased, suggesting a HIF isoform-specific kinetics of target gene 
expression.8, 14, 15 In contrast to the many known HIF-1 and HIF-1/HIF-2 target 
genes,8, 14, 16 only few genes have been reported to be regulated exclusively by HIF-
2, including erythropoietin, ephrin A1, VE-cadherin, protein tyrosine phosphatase 
receptor-type Z polypeptide 1, amphiregulin, and Wnt-1 induced signalling protein 2 
(WISP-2).8, 14, 17-21 
WISP-2 is a secreted protein member of the connective tissue growth factor/cysteine-
rich 61/nephroblastoma overexpressed (CCN) family, and is also known as CCN5.22, 
23 WISP-2 has been detected in adult skeletal muscle, colon, ovary and fetal lung, as 
well as in the stroma of breast tumours derived from Wnt-1 transgenic animals.24 
WISP-2 expression has been shown, in most studies, to inversely correlate with the 
aggressiveness of breast, pancreatic and colon cancer, suggesting a tumour 
suppressor-like activity.25, 26 WISP-2 shows transiently elevated levels during breast 
cancer progression: while it is almost undetectable in normal human mammary 
epithelial cells, it is highly expressed in estrogen receptor (ER) positive non-invasive 
breast cancer cell lines (including MCF-7, BT-474, ZR-75-1, T-47D), and again 
undetectable in ER negative highly invasive cells (including MDA-MB-231, MDA-MB-
468, BT-20 and DU-4475).27-30 Loss of WISP-2 in MCF-7 cells induced an estrogen-
independent growth and promoted epithelial-to-mesenchymal transition, consistent 
with a more invasive phenotype, whereas forced WISP-2 expression in MDA-MB-231 
cells reduced proliferation and invasiveness.30 WISP-2 expression is induced by 
estrogens as well as by epidermal growth factor (EGF) and insulin-like growth factor 
(IGF-1) in ER-positive cells, and WISP-2 is necessary for estrogen and IGF-1 
induced proliferation.31-35  
A functional estrogen response element (ERE) has been identified in the WISP-2 
promoter which is required for the estrogen inducibility of the WISP-2 gene.29 ER 
recruits the histone acetyl transferase CREB-binding protein (CBP) as well as the 
cyclin-dependent kinase inhibitor p21WAF1/CIP1 to the WISP-2 promoter, suggesting a 
cooperative control of WISP-2 gene expression.29, 36 Hypoxia has been identified as 
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another stimulus of WISP-2 gene expression which is mediated specifically by HIF-
2 in cooperation with the ETS oncogene family member ELK-1 in MCF-7 cells.14, 37 
We previously demonstrated that the WISP-2 promoter is induced specifically by HIF-
2 in MCF-7 cells.8 Here, we identified the hypoxia response elements (HREs) and 
characterized a microsatellite region responsible for the HIF-2-specific induction of 
the WISP-2 promoter. Furthermore, we assessed the impact of hypoxia and HIF-2 
on WISP-2 mediated cell proliferation, clonogenic growth and motility. 
 
5.3 Material and methods 
Cell culture and transfection 
Human breast cancer cell lines MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-468 and 
MDA-MB-231 were cultured in high-glucose Dulbecco's Modified Eagle's Medium 
(DMEM; Sigma-Aldrich, St Louis, MO, USA). Hypoxic experiments were performed at 
1% oxygen and 5% CO2 in a gas-controlled glove box (InvivO2 400; Ruskinn 
Technology Ltd, Bridgend, United Kingdom) as described previously.38 Viral particles 
were generated in HEK293T cells following co-transfection of the transfer vector (3 
g) together with the packaging plasmids pLP1 (4.2 g), pLP2 (2 g) and pVSV-G 
(2.8 g) (Invitrogen, Carlsbad, CA, USA) using polyethylenimine (Polysciences, 
Warrington, PA, USA). MCF-7 cells were infected with viral particles and cell pools 
were selected with puromycin as described before.38 Two independent WISP-2 
shRNA vectors (TRCN0000033355 and TRCN0000033357) were obtained from 
Sigma-Aldrich. shRNA resistant HIF-2 was used to rescue MCF-7 cells with stable 
HIF-2 knock-down as described before.8 
mRNA and protein detection 
Total cellular RNA was extracted as previously described.39 Total RNA (2 g) was 
reverse transcribed (RT) using AffinityScript reverse transcriptase (Agilent, Santa 
Clara, CA, USA) and the cDNA levels were estimated by quantitative (q) PCR using a 
SybrGreen qPCR reagent kit (Sigma-Aldrich) in a MX3000P light cycler (Agilent). 
Transcript levels were calculated by comparison with a calibrated standard and 
expressed as ratios relative to ribosomal protein L28 mRNA levels. Immunoblots 
were performed as previously described.40 Antibodies against the following proteins 
were used: WISP-2 (Abcam, Cambridge, United Kingdom), HIF-1 (BD Transduction 
Laboratories, Allschwil, Switzerland), HIF-2 (Novus Biologicals, Littleton, CO, USA), 
Sp1 (Santa Cruz Biotechnology, Dallas, TX, USA), and -actin (Sigma-Aldrich). 
Breast cancer tissue microarray analysis has been described previously.8 
Plasmid construction and reporter gene assays 
The promoter truncations -1919/+16, -808/+16, -520/+16, and -422/+16 have been 
reported previously29 and were kindly provided by M. Sabbah (Paris, France); -422/-
75, -83/+16 and MS deletions were generated by standard cloning techniques. The 
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WRE1, CRE, ELK-1 and WRE2 sites in the -422/+16 construct were mutated by site-
directed mutagenesis. The -252/+16 truncation was generated by PCR cloning. The -
422 (CA)n promoter region was amplified from T47D genomic DNA, transformed into 
bacteria, and isolated for sequencing to determine the CA repeat length. The -
112/+16 and the -112/+16 HRE2/3 double-mutant constructs were generated by 
elongation of an internal MluI site using double-stranded oligonucleotides. HRE2 and 
HRE3 in the -422/+16 construct were mutated by site-directed mutagenesis (5'-
CGTG-3' to 5'-CAAA-3'). Dual luciferase reporter gene assays were performed as 
described previously.41 
Genomic DNA extraction and sequencing 
Cells were washed with PBS, re-suspended in high salt lysis buffer (200 mM NaCl, 
50 mM Tris/HCl pH 8.0, 50 mM EDTA pH 8.0, 1% SDS) and treated overnight with 
proteinase K (20 mg/ml). After addition of saturated NaCl, DNA was precipitated with 
isopropanol, washed with 70% ethanol and re-suspended in Tris/EDTA buffer. WISP-
2 genomic DNA was amplified by PCR using forward primer 5'-
tacgggtaccacggacaggcacccccttggtgg-3' and reverse primer 5'-
cagatgtgcagagccagcagctt-3'. PCR products were gel-purified and sequenced 
(Microsynth, Balgach, Switzerland).  
Cellular proliferation, colony formation and motility assays 
To determine cell proliferation and viability, 105 cells per well were seeded into 6-well 
plates, allowed to adhere overnight, exposed to normoxia or hypoxia for 0 to 72 
hours, detached by trypsin/EDTA and counted using a Beckman Coulter Vi-cell TM 
XR Cell Viability Analyser (Brea, CA, USA). For low cell density colony forming 
assays, 2x103 cells per well were plated into 6-well plates, allowed to adhere 
overnight, and exposed to normoxia or hypoxia for 10 days with the medium replaced 
every 3 days. The colonies were fixed with methanol, stained with 0.5% crystal violet 
and counted. For anchorage independent colony formation assays, 104 cells were re-
suspended in 2 ml 0.4% low melting agarose (Sigma-Aldrich) in DMEM, poured on 
top of a 2% low melting agarose layer in 6-well plates and allowed to settle overnight. 
Following exposure to normoxia or hypoxia for 14 days, the soft agar was washed 
with PBS, the colonies stained with 0.005% crystal violet in methanol for 1 hour at 
room temperature, and counted. For scratch assay, cells were allowed to grow to 
100% confluency in 12-well plates. Following crosswise scratching with a 200 l 
pipette tip, the cells were exposed to normoxia or hypoxia in FCS-free DMEM for 24 
hours. The cell-free area was measured and converted to % recovery.  
Statistical analyses 
If not indicated otherwise, unpaired Student's t-tests were applied. Differences 
between two values were considered statistical significant if p < 0.05. Asterisks 
shown in the figures indicate the following levels of significance: *, p < 0.05; **, p < 
0.01; ***, p < 0.001. 
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5.4 Results 
The HIF isoform responsible for hypoxic WISP-2 induction is specific for 
distinct breast cancer cell lines 
To determine the HIF isoform directing WISP-2 expression in breast cancer, four 
luminal-like (MCF-7, BT-474, T-47D and ZR-75-1), one basal A-like (MDA-MB-468) 
and one basal B-like (MDA-MB-231) human breast cancer cell line were analyzed. 
Similar to data published previously,8, 30 constitutive WISP-2 mRNA levels were high 
in MCF-7 cells, moderate in T-47D and BT-474 cells, low in ZR-75-1 and almost 
undetectable in MDA-MB-231 and MDA-MB-468 (Figure 1A). Although WISP-2 
immunoblotting is notoriously difficult,42 probably because the WISP-2 protein is 
partially secreted, at least in MCF-7 cells also WISP-2 protein could be detected and 
was found to be upregulated following hypoxic stimulation (Figure 1B), like previously 
published for the WISP-2 mRNA levels.8  
Immunoblot analyses revealed that all six cell lines express both HIF-1 and HIF-2 
in a hypoxia-inducible manner (Figure 1C). The variable relative molecular weight of 
HIF-1 between approx. 98 to 120 kDa, as observed in the different cell lines, is due 
to varying degrees of phosphorylation like reported previously.43 HIF-1 and HIF-2 
were stably knocked-down by viral transduction of shRNA constructs. Exogenous 
shRNA expression efficiently reduced HIF levels (Figure 1C). In the absence of 
HIF-1 increased HIF-2 protein levels could be observed in most cell lines, a 
currently unexplained phenomenon that we and others described previously.8, 44 
In addition to MCF-7 cells8, a robust hypoxic WISP-2 mRNA induction was also found 
in T-47D, BT-474 and ZR-75-1 cells (Figure 1D). No hypoxic WISP-2 induction could 
be detected in MDA-MB-231 and MDA-MB-468 cells (data not shown). The knock-
down of the HIF isoforms demonstrated that WISP-2 mRNA is predominantly 
regulated by HIF-2 in MCF-7 and T-47D cells (Figure 1D). In MCF-7 cells, HIF-2 
shRNA also prevented the hypoxic induction of WISP-2 but not of prolyl-4-
hydroxylase domain 2 (PHD2) protein levels, the latter being a HIF-1 target (Figure 
1B). However, in BT-474 cells hypoxic WISP-2 mRNA induction was HIF-1 but not 
HIF-2 dependent, and in ZR-75-1 cells hypoxic WISP-2 mRNA induction was 
attenuated in the absence of both HIF-1 and HIF-2 (Figure 1D). These data 
demonstrate that WISP-2 is regulated by hypoxia in low-invasive luminal-like breast 
cancer cell lines and that cancer-specific HIF isoforms confer hypoxic WISP-2 
induction. 
Potential enhancer elements involved in HIF-inducible WISP-2 promoter activity  
To further investigate HIF isoform specific effect on WISP-2 transcription, we tested 
various WISP-2 promoter truncations driving firefly luciferase reporter gene 
expression in MCF-7 cells. All constructs ranging from -1929/+16 to -422/+16 relative 
to the transcriptional start site (TSS) of the human WISP2 gene displayed similar 
promoter activities. In contrast to the robust hypoxic WISP-2 mRNA induction (Figure 
Chapter 5: Manuscript I. Hypoxia. 2014; 2:23-33 
48 
 
1C), only weak responses to hypoxia could be observed with these reporter gene 
constructs (Figure 2A). Whereas moderate increases in promoter activity, mainly 
under hypoxic conditions, were observed after HIF-1 overexpression, strong 
increases in normoxic as well as hypoxic promoter activities followed HIF-2 
overexpression, suggesting that HREs likely are present on these constructs but are 
not sufficient to confer full hypoxic inducibility. Additional truncations of the -422/+16 
construct resulted in the complete loss of promoter activity in the absence of the 
region close to the TATA-like box (construct -422/-75), demonstrating that the first 75 
bp are essential for basal promoter activity. Normal basal activity but 
unresponsiveness to HIF overexpression was observed for construct -83/+16 
(Figure 2B).  
Three single putative HREs (HRE1, HRE2 and HRE3) and a double HRE (HRE4) 
were identified in the WISP2 promoter region (Figure 2C). Of note, the three single 
HREs were all located within microsatellite (MS) regions. HRE1 was found in a CA 
repeat region denominated MS I, HRE2 was located at the transition between a GT 
and a GC repeat, collectively named MS II, and HRE3 was identified within the GC 
repeat of MS II (Figure 2C). Furthermore, a phylogenetic footprint analysis of the 
promoter region revealed a strong sequence conservation around the TATA-like box, 
comprising a potential cAMP response element (CRE), a binding site for the Ets-like 
gene 1 (ELK-1), and two WNT responsive elements (WREs) (Figure 2C). However, 
when tested in MCF-7 shH2a cells with suppressed endogenous HIF-2 levels, 
WRE1 mutation neither affected basal promoter activity nor HIF responsiveness. 
Mutation of the CRE site strongly decreased promoter activity but partially retained 
HIF-2 -mediated induction. Similarly, the ELK and WRE2 mutations reduced overall 
promoter activity and slightly affected the HIF-2 -responsiveness (Figure 2D). In 
conclusion, these conserved elements are mainly required for basal promoter activity 
but do not seem to confer the HIF-2 -dependent induction of the WISP2 promoter, 
although we cannot exclude a partial cooperation between these cis-acting elements 
with the HREs.  
Two HREs within a microsatellite repeat regulate HIF-dependent WISP-2 
transcription 
To identify the HRE(s) responsible for HIF-mediated WISP-2 regulation, MS I 
(containing HRE1) was removed by a -252/+16 promoter truncation (MSI), and MS 
II (containing HRE2 and HRE3) was removed by a promoter deletion (MSII) as 
indicated in Figure 2C. Overexpression of both HIF isoforms in MCF-7 stable HIF-
2 knock-down (shH2a) cells was used to drive reporter gene expression. HIF -
dependent induction of the MSI construct in MCF-7 shH2a cells was 
indistinguishable from the -411/+16 construct, indicating that MS I does not contain a 
functional HRE. In contrast, HIF -dependent induction of reporter gene activity was 
strongly reduced when MS II was deleted (Figure 3A).  
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Deletion of the MS II resulted in basal reporter gene expression comparable to the 
minimal WISP-2 promoter (-83/+16) activity (Figure 3B). These experiments were 
repeated in MCF-7 wild-type cells with similar outcome (data not shown). 
Furthermore, the -83/+16 minimal promoter construct was extended with 
oligonucleotides containing either wild-type (-112/+16) or mutated (-112/+16mut) 
HRE2 and HRE3 as indicated in Figure 2C. While no differences in activity were 
observed between the -112/+16mut and the -83/+16 constructs, a partial but 
significant reconstitution of the HIF-2-mediated WISP-2 promoter induction was 
observed with the -112/+16 construct under hypoxic conditions (Figure 3B). In 
conclusion, these results demonstrate that HRE2 and/or HRE3 within MS II mainly 
confer HIF responsiveness to the WISP-2 promoter. 
Because MS instability is a hallmark of cancer,45 we tested whether differences in the 
length of the CA repeats in MS II might influence HIF -inducible promoter activity. 
Therefore, genomic DNA from T-47D cells was amplified and cloned. CA repeat 
length variants CA12, CA13, CA17 and CA18 were obtained and compared to the 
parental -422/+16 construct derived from MCF-7 cells (Figure 3C). However, no 
change in reporter gene activity could be observed, suggesting that MS instability 
does not affect HIF-mediated WISP-2 promoter activity. 
Unexpectedly, sequencing of the WISP2 upstream regulatory region revealed the 
presence of HRE2 in all breast cancer cell lines analyzed in Figure 1, as well as in 
Hep3B and HepG2 hepatoma, SK-N-MC neuroepithelioma and HeLa cervical 
carcinoma, but not in three published sequences (GRCh37.p2, HuRef and 
Hs_Celera). Only UT-7 megakaryoblastic leukemia cells lacked HRE2 and showed 
the same sequence like the database entries (data not shown). Therefore, the -
252/+16 region was amplified from UT-7 cells (-252/+16_UT7) and compared with 
the promoter constructs derived from MCF-7 cells. Only a small reduction in 
response to HIF overexpression was observed with the -252/+16_UT7 construct 
(Figure 3D). Also mutation of HRE3 (HRE3) resulted in a modest reduction in 
reporter gene activity, and a double mutation of HRE2 and HRE3 (HRE2/HRE3) 
further abrogated reporter gene activity comparable to the one observed after 
deletion of MS II (Figure 3E). Taken together these results indicate that the two HREs 
within MS II mediate at least partially HIF -dependent induction of the WISP-2 
promoter.  
WISP-2 negatively correlates with tumour infiltration by macrophages 
We previously reported that high WISP-2 levels positively correlate with high HIF-2 
levels and prolonged overall survival in breast cancer patients.8 Because tumour 
macrophage infiltration, associated with the hypoxic tumour microenvironment and 
high HIF levels, not only represents an important step during breast cancer 
progression but also an important prognostic marker,46, 47 we analysed whether 
WISP-2 expression levels are related to tumour-associated macrophage counts. 
Therefore, over 300 breast cancer samples were immunostained and scored for the 
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macrophage markers CD68 and CD163 and the pan-leukocyte marker CD45 (Figure 
4A). Interestingly, a negative correlation between WISP-2 and tumour-associated 
macrophage counts was found (Figure 4B). As expected, overall survival of these 
patients was negatively associated with macrophage infiltration (Figure 4C). These 
results suggest that HIF-2 mediated WISP-2 expression is a marker for (and maybe 
is even causally involved in) breast cancer progression stage with low cancer cell 
proliferation/invasiveness as well as low macrophage infiltration, both contributing to 
improved prognosis. 
HIF modulates the WISP-2 suppressed motility of MCF-7 cells 
Silencing of WISP-2 in non-invasive MCF-7 cells has been reported to enhance 
motility and modulate the expression of genes involved in cancer invasiveness.30, 48, 
49 To investigate the functional consequences of HIF mediated WISP-2 regulation, 
we stably transfected MCF-7 cells with WISP-2 shRNA, resulting in a robust knock-
down of WISP-2 mRNA using two independent shRNA constructs (shW#1 and 
shW#2) under normoxic as well as hypoxic conditions (Figure 5A). Proliferation of 
both WISP-2 knock-down cells, but not of previously established HIF-2 knock-down 
cells8 was significantly impaired under both normoxic and hypoxic conditions (Figure 
5B). As determined by automated trypan blue exclusion and video microscopy 
analysis, no difference in gross cell morphology or viability could be observed (data 
not shown). Low cell density colony formation was somewhat attenuated by knock-
down of both HIF-2 and WISP-2 (Figure 5C). In contrast, anchorage independent 
colony formation was increased; especially in normoxic cells (Figure 5D). Similarly, 
recovery from scratches in confluent cell layers was significantly increased by knock-
down of both HIF-2 and WISP-2 (Figure 5E). Probably owing to a remaining weak 
WISP-2 induction (see Figure 5A), under hypoxic conditions a slightly impaired 
anchorage-independent colony formation (Figure 5D) as well as scratch recovery of 
MCF-7 cells was observed (Figure 5E), though the values were still higher than in the 
hypoxic control cells. In summary, these results are consistent with a role of HIF-2 in 
the WISP-2 mediated suppression of MCF-7 anchorage independent growth and cell 
motility, two hallmarks of cancer progression.  
 
5.5 Discussion 
In this study, we could corroborate the previously reported hypoxic induction of 
WISP-28 which was HIF-2 dependent in most but not all low invasive breast cancer 
cell lines tested, suggesting that currently unknown cell type-specific co-factors 
determine the HIF isoform responsible for hypoxic WISP-2 induction, rather than 
intrinsic gene selectivity of the HIF isoforms themselves. Previous studies 
suggested a cooperation of HIF-2, but not HIF-1, with ETS factors resulting in 
target selectivity14, 50 but whether a different composition of ETS factors explains the 
HIF-1 specific WISP-2 expression in BT-474 cells remains to be explored. Although 
we observed lower basal levels of WISP-2 promoter activity following mutation of the 
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conserved CRE, ELK-1 and WRE sites, HIF-2 mediated WISP-2 regulation 
remained unaffected, suggesting that none of these factors confers HIF isoform 
selectivity. 
Two functional HREs were identified which are essential for HIF-2 specific 
induction of WISP-2 promoter activity in MCF-7 cells, but even promoter constructs 
up to 1919 bp upstream of the TSS did not fully recapitulate the hypoxic induction 
factors determined at the mRNA level. Of note, in a genome-wide chromatin 
immunoprecipitation study both HIF isoforms were reported to bind to a region 
within the first intron of WISP-251 suggesting that these elements might contribute to 
endogenous WISP-2 regulation. However, at least in MCF-7 cells we could not detect 
any further increase in hypoxic WISP-2 transcription by this region in combination 
with the upstream regulatory elements (data not shown). The two functional HREs 
are located within the highly polymorphic MS II region of the WISP-2 promoter. Such 
unstable polymorphic di-nucleotide repeats are known to play an important role in 
tumour progression. Microsatellite instability seems to be mostly due to the loss of 
functional mismatch repair machinery and is implicated in prognosis and therapy 
response because it alters the expression levels of the affected genes.45, 52 However, 
we could not find any role for MS II length in regulating reporter constructs driven by 
the WISP-2 promoter. 
By immunohistochemical analysis of breast cancer samples we recently 
demonstrated that HIF-2 and WISP-2 levels correlate with a more differentiated 
tumour cell type and consistently with a better prognosis.8 These results are in line 
with the findings presented herein showing that WISP-2 negatively correlates with 
tumour macrophage invasion, which provides an additional marker for a better 
tumour prognosis. Silencing of WISP-2 elevated two parameters of cancer cell 
aggressiveness: anchorage-independent colony formation as well as recovery from 
scratches in confluent cell layers. These effects could not simply be explained by 
changes in proliferation rates and anchorage-dependent colony formation which were 
actually slightly decreased rather the increased. Interestingly, increased anchorage-
independent colony formation and scratch recovery following WISP-2 knock-down 
could be phenocopied by HIF-2 silencing. While we cannot exclude that additional 
signalling pathways are recruited by the hypoxic tumour microenvironment, our data 
strongly suggest that HIF-2 mediated WISP-2 induction contributes to a less 
aggressive tumour type. 
 
5.6 Conclusion 
Taken together, our data suggest that the previously reported association between 
high HIF-2 levels and an increased overall survival rate of breast cancer patients 
could be explained at least partially by HIF-2 mediated direct induction of WISP-2, 
maintaining a less aggressive breast cancer phenotype. 
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5.8 Figures  
 
Figure 1 HIF isoform-specific regulation of WISP-2 transcription. (A) Basal WISP-2 mRNA levels 
were determined by RT-qPCR in the six breast cancer cell lines indicated using a calibrated internal 
standard. Shown are mean values ± SEM of n = 3 independent experiments. (B) MCF-7 cells were 
cultured in normoxia or exposed to hypoxia for 24 hours, and analysed by immunoblotting using 
antibodies derived against WISP-2, the HIF target PHD2, HIF-2 or the constitutively expressed 
control protein -actin. (C) Cells were stably transfected with either control (ctrl.) shRNA or shRNAs 
targeting HIF-1 (shH1a) or HIF-2 (shH2a) and analysed by immunoblotting of nuclear extracts 
using antibodies derived against HIF-1, HIF-2 or the constitutively expressed control transcription 
factor Sp1. (D) Hypoxic WISP-2 mRNA induction was determined in the indicated cell lines which were 
stably transfected with either control (ctrl.) or shRNA constructs as in (C). WISP-2 mRNA levels were 
quantified by RT-qPCR and normalized to the mRNA levels of the ribosomal protein L28. Shown are 
mean values ± SEM of n = 3 independent experiments. (D) For statistical evaluation of the hypoxically 
exposed cells, the effects of HIF-1 or HIF-2 silencing were compared to the control shRNA 
transfected cells. 
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Figure 2 Characterization of the WISP2 promoter. Dual luciferase reporter gene experiments in MCF-
7 cells, transfected with either HIF-1 or HIF-2 overexpression vectors together with the indicated 
firefly luciferase vectors and a renilla luciferase control vector, after 24 hours under normoxic or 
hypoxic (1% O2) conditions. (A) Promoter truncations from positions -1919 to -422 upstream of the 
TSS. (B) Potential HREs are depicted by black marks (upper panel). HIF responsiveness was lost in 
the minimal promoter (lower panel). (C) Four potential HREs in the WISP2 5' flanking region are 
indicated in red colour. MS, microsatellite repeat; GB, Gene Bank. (D) MCF-7 shH2a cells were co-
transfected with either the wild-type (-422) promoter construct, or constructs bearing the indicated 
mutations, together with either an empty (e) vector, a HIF-1 (H1) or a HIF-2 (H2) overexpression 
vector. Shown are mean values ± SD of n = 3 (4 for D) independent experiments performed in 
triplicates. For statistical evaluation, the effects of HIF-1 and HIF-2 overexpression have been 
compared to the respective empty vector controls (A, B), or were first normalized to the empty vector 
control values and then compared to the respective normalized values of the wild-type -422/+16 
promoter construct (D). 
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Figure 3 Identification of the HREs responsible for HIF-mediated induction of WISP-2 transcription. 
Dual luciferase reporter gene experiments in MCF-7 shH2a cells, transfected with either an empty (e), 
a HIF-1 (H1) or a HIF-2 (H2) overexpression vector together with the indicated firefly luciferase 
constructs and a renilla luciferase control vector, after 24 hours under normoxic or hypoxic (1% O2) 
conditions. (A) WISP-2 promoter constructs lacking either MS I (MSI) or MS II (MSII) were 
compared with the -422/+16 construct. (B) WISP-2 promoter constructs containing wild-type (-
112/+16) or mutant HRE2 and HRE3 (-112/+16mut) were compared with the MSI, MSII or minimal 
promoter (-83/+16) constructs. (C) WISP-2 promoter constructs containing the indicated MS repeat 
length polymorphisms identified in T-47D cells were compared with the -422/+16 fragment derived 
from MCF-7 cells. (D) WISP-2 promoter constructs containing the HRE2-deficient sequence identified 
in UT-7 cells (-252/+16_UT7) were compared with the corresponding fragment (-252/+16) and the 
minimal promoter (-83/+16) derived from MCF-7 cells. A to D) Shown are mean values ± SD of 
representative experiments performed in quadruplicates. (E) WISP-2 promoter constructs containing 
the -252/+16 fragment, either wild-type (-252/+16), HRE2 mutant (HRE2) or HRE2 and HRE3 double 
mutant (HRE2/HRE3), were compared with the MSII construct. Shown are mean values ± SD of 
n = 3 independent experiments performed in quadruplicates. For statistical evaluation, the effects of 
HIF-1 and HIF-2 overexpression were first normalized to the empty vector control values and then 
compared to the respective normalized values of the wild-type -422/+16 (A, C) or the -252/+16 (D, E) 
promoter constructs. (B) Similarly, the activities of -112/+16 and -112/+16mut were compared to the -
83/+16 minimal promoter. 
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Figure 4 WISP-2 correlations with macrophage infiltration of human breast cancer tissues. (A) 
Exemplary spots of breast cancer tissue micro arrays immunostained for CD45, CD68 and CD163 
macrophage markers. Numbers in upper left corners indicate categorization of staining intensity: 0/1, 
sparse; 2, moderate; 3, extensive. (B) Negative correlation of WISP-2 expression with macrophage 
markers CD68 and CD163 in 331 and 321, respectively, human breast cancer samples. (C) Negative 
prognostic correlation between overall survival of breast cancer patients and high infiltration levels with 
CD68-positive tumour associated macrophages. 
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Figure 5 Role of HIF-2 and WISP-2 in MCF-7 proliferation and motility. (A) MCF-7 cells were stably 
transfected by lentiviral infection with control (ctrl.) or two independent WISP-2 shRNA constructs 
(shW#1 and shW#2). Following normoxic or hypoxic (24 hours, 0.2% O2) exposure, WISP-2 mRNA 
levels were determined by RT-qPCR and normalized to the mRNA levels of the ribosomal protein L28. 
Shown are mean values ± SD of n = 5 independent experiments. (B) Proliferation of MCF-7 cells kept 
under normoxic or hypoxic conditions for up to 3 days was determined by cell counting, and cell 
numbers were normalized to the number of cells initially seeded. Shown are mean values ± SD of n = 
3 independent experiments performed in triplicates. Differences after 3 days relative to the un-
transfected controls were analysed by Student's t-test (*p<0.05, ***p<0.001). (C) Low density colony 
formation of MCF-7 cells cultured under normoxic or hypoxic conditions for 10 days. Shown are the 
colony numbers of n = 3 triplicate measurements and the corresponding mean values. (D) Anchorage 
independent colony formation of MCF-7 cells cultured in soft agar under normoxic or hypoxic 
conditions for 14 days. Shown are the colony numbers of n = 4 to 5 triplicate measurements and the 
corresponding mean values. (E) Recovery of scratched confluent MCF-7 cell layers after 24 hours of 
normoxic (Norm.) or 0.2% O2 hypoxic (Hyp.) exposure. Shown are the results of 4 to 5 independent 
experiments. (A to E) For statistical evaluation, the values were compared to the respective control 
shRNA transfected cells. 
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6. Unpublished manuscript: WISP-2 and its function in 
MCF-7 
6.1 Introduction 
Detection and determination of WISP-2 are complicated due to the nature of WISP-2 
as a secreted protein and the previous lack of effective antibodies against WISP-2. 
Here, I describe several approaches I performed in order to detect and quantify 
WISP-2 in the MCF-7 breast cancer cell line. 
Induction of estrogen-independent growth and promotion of epithelial-to-
mesenchymal transition (EMT) have been observed in WISP-2 knocked down breast 
cancer cells173. In addition, microarray gene expression analysis revealed that WISP-
2 represses expression of genes associated with EMT162. Furthermore, 
overexpression of WISP-2 in the highly invasive breast cancer cell line MDA-MB-231 
results in reduction of proliferation and invasiveness173. Together with the biphasic 
nature of WISP-2 expression in breast cancer cells, these observations suggest the 
potential roles of WISP-2 as an anti-invasive factor in breast cancer. In this thesis, I 
aimed to functionally explore the consequences of WISP-2 regulation by hypoxia, 
therefore I first investigated the mRNA levels of several genes reported to be 
involved in EMT. The genes I selected are MMP9, E-cadherin, and vimentin. 
MMP9 is one of the most intensely investigated matrix metalloproteinase (MMP) and 
is involved in various physiological and pathophysiological roles. Physiologically, 
MMP9 has been shown to be essential for embryonic implantation and has also been 
reported to play a significant role in neovascularisation238,239. In pathophysiological 
conditions involving inflammatory processes, such as rheumatoid arthritis and 
cancer, MMP9 is overexpressed240,241. E-cadherin is a calcium-dependent cell-cell 
adhesion molecule, a member of the cadherin superfamily and a known tumour 
suppressor protein242. It is well established that the loss of E-cadherin is correlated 
with tumour progression and that the loss of E-cadherin plays a role in increasing the 
motility of cancer cells and hence promoting invasion and metastasis243,244. In 
contrast to E-cadherin, which is highly expressed in epithelial cells, vimentin is highly 
expressed in mesenchymal cells245. Vimentin is a type III intermediate filament (IF) 
protein and is a major cytoskeletal component responsible for the maintenance of cell 
integrity245. Due to its high expression in mesenchymal cells, vimentin, together with 
E-cadherin, is considered as a marker of cells undergoing EMT245. 
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6.2 Materials and methods 
6.2.1 Cell culture and reagents 
Human breast cancer cell lines MCF-7 and MDA-MB-231 were cultured in Dulbecco’s 
Modified Eagle’s Medium (DMEM; Sigma-Aldrich, St Louis, MO, USA) supplemented 
with 1% or 10% heat-inactivated foetal calf-serum (FCS), 50 IU/ml penicillin and 50 
μg/ml streptomycin (Invitrogen). Hypoxia experiments were performed at the 
indicated concentration of oxygen (O2) and 5% carbon dioxide (CO2) in a gas-
controlled glove box (InvivO2 400, Baker Ruskinn, Bridgend, UK).  
6.2.2 mRNA detection and quantification 
Cellular RNA was extracted using the phenol-chloroform protocol and cDNA was 
generated by reverse transcription (RT) from 2 μg total RNA using AffinityScript 
reverse transcriptase (Agilent). Transcript levels were estimated by quantitative (q) 
PCR using a SybrGreen qPCR reagent kit (Sigma-Aldrich) in a MX3000P light cycler 
(Agilent). Ribosomal protein L28 mRNA levels were used as normaliser. Primers 
used are listed in table 1.  
Gene Forward primer Reverse primer Amplicon 
size 
MMP9 TTGACAGCGACAAGAAGTGG 
 
GCCATTCACGTCGTCCTTAT 
 
179 
E-cadherin TGCCCAGAAAATGAAAAAGG 
 
GTGTATGTGGCAATGCGTTC 
 
200 
Vimentin GAGAACTTTGCCGTTGAAGC 
 
TCCAGCAGCTTCCTGTAGGT 
 
170 
L28 GCAATTCCTTCCGCTACAAC 
 
TGTTCTTGCGGATCATGTGT 198 
  
6.2.3 Immunoblotting 
Combined cytoplasmic and nuclear extracts were prepared using the following lysis 
buffers: TNMG lysis buffer (20 mM Tris-HCl (pH 8.0), 150 mM NaCl, 5 mM MgCl2, 
0.5% Nonidet P-40, 10% glycerol, 1 mM sodium vanadate and protease inhibitor 
cocktail), NTEN lysis buffer (50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.2 mM EDTA, 
1% Nonidet P-40, 1mM phenylmethylsulfonyl fluoride and 1 x protease inhibitor 
cocktail), and RIPA lysis buffer (50 mM Tris-HCl (pH 7.4), 1% Nonidet P-40, 0.5% 
Na-deoxycholate, 0.1% SDS, 150 mM NaCl, 2 mM EDTA, 50 mM NaF, 1 mM 
phenylmethylsulfonyl and 1 x protease inhibitor cocktail). Protein concentration was 
determined by the bicinchoninic acid assay method and up to 50 μg cellular protein 
was subjected to immunoblot analysis. Antibodies against the following proteins were 
used: WISP-2 (Abcam, Santa Cruz, and USCN), HIF-1α (BD Transduction 
Laboratories, Allschwil, Switzerland), HIF-2α (Novus Biologicals, Littleton, CO, USA), 
PHD2 and β-actin (Sigma-Aldrich).  
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6.2.4 Human WISP-2 enzyme-linked immunosorbent assay (ELISA) 
Briefly, 1.5 to 2 x 106 cells were plated on a 10 cm2 plate. The day after seeding, 
medium was replaced with 10 ml DMEM supplemented with 1% FCS without 
antibiotics and cells were exposed to 20% or 0.2% O2 for the stated time duration. 
For the specified experiments, medium was collected and filtered consecutively with 
filters of three different cut offs (50 kDa, 30 kDa, and 10 kDa) (Amicon Ultra-4 
centrifugal filter units). Concentrates and filtrates were collected and tested. Human 
WISP-2 ELISA (E96894Hu ELISA kit for WISP-2, USCN Ltd) was performed 
according to the manufacturer’s instruction. 
6.2.5 Immunofluorescence 
1 x 105 MCF-7 cells were plated in 12-well plates on top a cover slip. A day later, cells 
were exposed to hypoxia for 24 hours. Cells were fixed in 0.4% paraformaldehyde in 
PBS, permeabilised in 0.1% Triton/PBS, blocked with 10% FCS/PBS, and exposed to 
rabbit-antihuman WISP-2 (A96894Hu, USCN Ltd). Secondary antibody (goat anti-
rabbit Alexa488) was used to visualise the cells. DAPI was used to visualise the 
nuclei. Samples were mounted in Mowiol and visualised using fluorescence 
microscope. 
6.2.6 Motility and Boyden chamber assays 
Briefly for motility assay, cells were grown to full confluency in 12-well plates. 
Following crosswire scratching with a 200 μl pipette tip, the cells were exposed to 
normoxia or hypoxia in FCS-free DMEM for 8 hours. For the treatment with 
recombinant WISP-2, 10 nM of recombinant WISP-2 was added to the cells right 
after scratching and exposed to normoxia or hypoxia. The cell-free area was 
measured and converted to percent recovery. To determine cell migration, a chamber 
(Corning Incorporated) containing an 8 μm pore size polycarbonate filter insert that 
divides the chamber into upper and lower portions was used. Briefly, 1 x 105 cells 
were seeded to the upper chamber of the insert, while the lower chamber was filled 
with 10% FCS supplemented DMEM. After allowing the assays to proceed for 20 
hours under normoxia or hypoxia, the cells on the top of the filter were removed by 
swabbing and the remaining cells on the bottom of the filter were stained with 
Giemsa and counted under a light microscope.   
6.2.7 Statistical analysis 
If not indicated otherwise, unpaired Student’s t-tests were applied. Differences 
between two values were considered statistical significant if p < 0.05. Asterisks 
shown in the figures indicate the following levels of significance: *, p < 0.05; **, p < 
0.01; ***, p < 0.001. 
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6.3 Results 
6.3.1 Detection of WISP-2 on MCF-7 
As WISP-2 is known to be a secreted protein, I performed ELISA to detect secreted 
WISP-2 (Figure 6.1). I confirmed the specificity of the ELISA by applying 1 ng 
recombinant WISP-2 protein in DMEM (1% FCS) and compared with control DMEM 
(1% FCS). I also attempted to determine the best lysis buffer for WISP-2 protein 
extraction and I observed higher WISP-2 levels using RIPA lysis buffer compared to 
TNMG and NTEN lysis buffers.  
To detect secreted WISP-2, I collected the supernatants from MCF-7 cells incubated 
for 24, 48, 72, 96, and 120 hours under normoxia. At the same time, I also collected 
supernatants from MCF-7 cells incubated under normoxia or hypoxia for 72 hours. I 
filtered the collected supernatants consecutively with filters of three different cut offs 
and applied both the concentrates and the ultrafiltrates on ELISA. I observed an 
increase in signals. However, I cannot conclude that the detected signals are derived 
from WISP-2 due to the inability of the filtration processes to differentiate the signals, 
suggesting the possibility of nonspecific binding of the antibody against non-WISP-2 
protein. The reported size of WISP-2 is 29 kDa and I expected to observe higher 
WISP-2 levels at the concentrate after filtration with 10 kDa filter. Lastly, I performed 
ELISA on protein extracts from manipulated breast cancer cell lines. I did observe 
lower levels of the supposedly WISP-2 on shHIF-2α MCF-7 and MDA-MB-231; 
however the shWISP-2 MCF-7 (#62) did not show reduced WISP-2 levels.        
I also performed immunofluorescence experiments to detect WISP-2 in MCF-7 and 
MDA-MB-231. However, I could not differentiate the signal since we detected signals 
also in the supposedly WISP-2 knocked down (KD) and negative cell lines, such as 
shWISP-2 and MDA-MB-231 (Figure 6.2).   
6.3.2 The role of WISP-2 in the aggressiveness of breast cancer cells 
As mentioned previously, WISP-2 has been shown to be particularly relevant in 
human breast cancer due to its biphasic expression nature. Functionally, the 
silencing of the WISP-2 gene results in reduced serum-dependent breast tumour cell 
proliferation173. Furthermore, the overexpression of this protein in highly invasive 
MDA-MB-231 results in reduced cell proliferation and invasiveness173. Based on 
these observations, we hypothesised a possible role of O2-regulated EMT by WISP-
2. We first investigated the changes of three EMT markers: MMP-9, E-cadherin and 
vimentin by HIF-1α and HIF-2α (Figure 6.3a). I then investigated the regulation of 
these EMT markers by WISP-2 (Figure 6.3b). Furthermore, I treated MCF-7 with 
recombinant WISP-2 at different time-course and different concentrations. 
Unfortunately, I could not observe any changes in the levels of EMT markers upon 
treatment with recombinant WISP-2.    
To study the functional roles of WISP-2, scratch recovery and Boyden chamber 
assays were performed (Figure 6.4). Consistent with the previously published 
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recovery of confluent cells after 24 hours, scratch recovery in confluent cell layers 
was significantly increased by knockdown of both HIF-2α and WISP-2 after 8 hours. 
To further confirm the roles of WISP-2 in cell motility, scratch recovery assays were 
performed with the addition of 10 nM recombinant WISP-2. Treatment with 10 nM 
recombinant WISP-2 did not result in significant changes in the scratch recovery rate. 
Moreover, Boyden chamber assay was utilised to investigate the roles of WISP-2 in 
the migratory capabilities of MCF-7. I observed a significant increase in migrated 
cells with the knockdown of HIF-2α. In general, I also observed an increase in cell 
migration for the knockdown of WISP-2 (both #62 and #64); however, the increases 
were not significant. 
 
6.4 Discussions 
As a secreted protein, WISP-2 protein detection presents a challenge, especially with 
the previous lack of specific antibodies. To complement immunoblotting I utilised 
multiple techniques such as ELISA and immunofluorescence in order to detect WISP-
2. ELISA is an ideal method in detecting secreted protein as supernatant from MCF-7 
cells can be collected and tested directly without further manipulation. I encountered 
difficulties with the usage of 10% FCS in the DMEM used with the maintenance of 
MCF-7. The 10% FCS is required for the optimum growth of MCF-7 cells; however it 
complicated the ELISA protocol with the introduction of multiple non-human proteins 
and resulted in background signals during WISP-2 detection. At the same time, MCF-
7 cells need the presence of 10% FCS as the absence of FCS resulted in increased 
cell deaths. As such, I decided to perform the experiments in the presence of 1% 
FCS. With this, I reduced the presence of non-human proteins and simultaneously 
maintain MCF-7 cells in a better condition.  
Knock down of WISP-2 in breast cancer cells has been reported to induce estrogen-
independent growth and promotion of EMT. In this thesis, I explored the potential role 
of WISP-2 in EMT. Functional assays such as scratch recovery and Boyden chamber 
assays were performed. Knock down of HIF-2 and WISP-2 in MCF-7 cells resulted 
in increased motility and migration, two characteristics of EMT. However, 
investigation of the levels of MMP9, E-cadherin and vimentin on HIF-2-KD and 
WISP-2 KD MCF-7 cells did not indicate the role of these genes in the increased 
motility and migration of MCF-7 cells. Hence my observations contradict the 
previously reported role of WISP-2 in EMT.   
To further confirm the reported role of WISP-2, I treated MCF-7 cells with 
recombinant WISP-2. The rationale is that if knockdown of WISP-2 in breast cancer 
cells promoted EMT, then the presence of WISP-2 might reverse this and hence 
promoted mesenchymal-to-epithelial transition (MET). Treatment of MCF-7 cells with 
recombinant WISP-2 at different concentrations or different time-points did not result 
in changes in MMP9, E-cadherin and vimentin, again contradicting the role of WISP-2 
in EMT. Moreover, treatment of MCF-7 with recombinant WISP-2 did not affect the 
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motility of MCF-7 cells. One could argue that the recombinant WISP-2 did not assert 
its role due to the fact that it might not be internalised into the cells. To counter this 
argument, overexpression of WISP-2 must be performed, followed by the 
quantification of gene changes and functional assays. 
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6.6 Figures 
 
Figure 6.1 ELISA was performed to detect WISP-2 (A) Standard curve of ELISA. (B) The specificity 
of the ELISA was tested by applying 1 ng recombinant WISP-2 (C) Different extraction protocols were 
used to determine the best lysis buffers for the extraction of WISP-2 protein from MCF-7 (D) Time-
dependent accumulation of WISP-2 in the supernatant of MCF-7 cells (E) Supernatant of MCF-7 cells 
incubated for 72 hours and filtered were tested for WISP-2 protein by ELISA. Conc. = concentrate of 
filtration protocol, Filt. = filtrate from the filtration protocol (F) ELISA was performed on protein extracts 
from MCF-7 shControl (shCt), shHIF-2α (shH2α), shWISP-2 (#62) and MDA-MB-231. 
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Figure 6.2 Immunofluorescence detection of WISP-2 in MCF-7 cells. MCF-7 WT, shControl 
(shCtrl), shHIF-2α, shWISP-2 and MDA-MB-231 WT cells were exposed to hypoxia (0.2% O2) for 24 
hours. Cells were then fixed and treated with rabbit-antihuman WISP-2. DAPI was used to stain the 
nuclei. 
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Figure 6.3 The effects of WISP-2 on epithelial-to-mesenchymal transition (EMT). MMP9, E-
cadherin, and vimentin were selected as markers for EMT. The mRNA levels of MMP9, E-cadherin 
and vimentin were quantified in (A) MCF-7 shCtrl (shCt), shHIF-1α (shH1α), shHIF-2α (shH2α), shHIF-
1/2α (shH1/2α), and (B) two different MCF-7 shWISP-2 (#62 and #64) under normoxia or hypoxia. (C) 
MCF-7 cells were treated with different concentrations of recombinant WISP-2 for 24 hours. (D) 10ng 
recombinant WISP-2 was applied on MCF-7 cells at different time points. Shown are mean values ± 
SEM of n=3 independent experiments.  
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Figure 6.4 Modulation of motility and migration by WISP-2. (A) Confluent cells were scratched and 
incubated for 8 hours under normoxia and hypoxia. (B) Scratched areas were measured before and 
after incubation and percentage recovery was calculated. (C) Cells were also treated with 10 nM 
recombinant WISP-2 for 24 hours. (C) Cell migration was investigated using Boyden chamber 
migration assay. Shown are mean values ± SEM of n=3 independent experiments.  
 
 
 
Chapter 7: Manuscript II. Submitted to Oncotarget 
74 
 
7. Manuscript II: Estrogen-dependent downregulation of 
hypoxia-inducible factor (HIF)-2 in invasive breast cancer 
cells 
Jerry H. Fuady1, Katrin Gutsche1, Sara Santambrogio1, Zsuzsanna Varga2, David 
Hoogewijs3, and Roland H. Wenger1 
 
1Institute of Physiology and Zurich Centre for Human Physiology (ZIHP), University of 
Zurich, 8057 Zurich, Switzerland 
2Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland 
3Institute of Physiology, University of Duisburg-Essen, Essen, Germany  
 
Correspondence: Roland H. Wenger, Institute of Physiology, University of Zurich, 
Winterthurerstrasse 190, 8057 Zurich, Switzerland. 
Tel: +41 44 6355065 
Fax: +41 44 6356814 
Email: roland.wenger@access.uzh.ch  
 
Keywords: ER, HER2, histone deacetylation, hormone therapy, tumor oxygenation 
  
Chapter 7: Manuscript II. Submitted to Oncotarget 
75 
 
7.1 Abstract 
The involvement of estrogen (E2) and hypoxia in the tumor progression is well 
established. Hypoxia has been reported to activate and degrade estrogen receptor 
alpha (ER) in breast cancer cells. Furthermore, E2 has been shown to regulate 
hypoxia-inducible factor (HIF)-1 protein, but its role in HIF-2 regulation remains 
largely unexplored. In this study, we found that both HIF-2 mRNA and protein were 
down-regulated in ER-positive but not ER-negative breast cancer cells upon 
treatment with E2. The analysis of 690 samples derived from 608 mixed and 82 
triple-negative breast cancer patients revealed that high HIF-2 tumor levels are 
associated with a better prognosis in human epidermal growth factor receptor 2 
(HER2)-positive patients. Consistently, hormone receptor and HER2-positive breast 
cancer cells displayed less pronounced downregulation of HIF-2 by E2. 
Experiments using histone deacetylase (HDAC) inhibitors indicate that the E2 
mediated decrease in HIF-2 mRNA is due to transcriptional repression. A functional 
estrogen response element (ERE) was identified in the first intron of EPAS1, 
suggesting transcriptional co-repressor recruitment by ER. Our results demonstrate 
a novel modulation of HIF-2 in breast cancer cells and might partially explain the 
association between high HIF-2 and better prognosis in triple-positive breast cancer 
patients. 
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7.2 Introduction 
The ability of cancer cells to adapt to micro-environmental tissue hypoxia is mainly 
mediated by hypoxia-inducible factors (HIFs), which affect every aspect of cancer 
progression, comprising metabolism, proliferation, inflammation, angiogenesis, 
metastasis and therapy resistance1-4. Transcriptionally active HIFs are heterodimers 
composed of a constitutively expressed  subunit and an oxygen labile HIF-1 or 
HIF-2 subunit, the stability and activity of which is regulated by prolyl-4-hydroxylase 
domain (PHD) and factor inhibiting HIF (FIH) enzymes5. Despite showing similar 
protein structures and having identical DNA recognition sequences, distinct - 
sometimes even opposite - functional roles of HIF-1 and HIF-2 in tumorigenesis 
have been reported6-9. We and others found different kinetics of hypoxic HIF-1 and 
HIF-2 protein induction and target gene expression10,11, further suggesting non-
overlapping roles for these two related transcription factors.  
Estrogens are steroid hormones and represent the primary female sex hormones, 
regulating diverse physiological processes in reproductive, mammary, 
cardiovascular, osseous, hepatic, and neuronal tissues12-16. The cellular effects of 
estrogen are mediated by two estrogen receptor (ER) isoforms, ER and ER, which 
belong to the family of nuclear hormone receptors17. Ligand binding leads to the 
dissociation of heat shock proteins from the ER, which is followed by receptor 
dimerization and nuclear translocation. In the nucleus, the activated dimer complex 
binds to estrogen response elements (EREs) located within the regulatory regions of 
target genes18.  
Besides regulating numerous aspects of human physiology, estrogens also influence 
diverse pathophysiological processes, including the onset and progression of breast 
cancer19. Breast cancer is the most common cancer in women worldwide and the 
second most common cancer overall. Approx. 1.7 million new cases were diagnosed 
in 2012, which represents 12% and 25% of all new cancer cases and all cancers in 
women, respectively20,21. The presence of elevated ER levels in benign breast 
epithelium correlates with an increased risk of breast cancer, suggesting a role for 
ER in breast cancer initiation22. 17-estradiol (E2), the dominant circulating 
estrogen, regulates the growth of many breast tumors and approx. 70% of breast 
cancers express ER. Most of these ER-positive tumors depend on estrogen 
signaling for their growth and survival23.  
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In conjunction with estrogen, hypoxia has been reported to play an important role in 
the development and progression of breast cancer24-28. In breast cancer cells, 
estrogen and hypoxia modulate the expression of genes involved in proliferation, 
differentiation, angiogenesis, metabolism and apoptosis29-31. Further studies revealed 
the presence of a cross-talk between estrogen signaling pathways and HIF-1 
regulation in breast cancer28,32. Estrogen has been reported to rapidly induce ER-c-
Src-PI3K interactions which activates the PI3K/AKT/mTOR pathway and subsequent 
HIF-1 protein translation by phosphorylation of the p70 S6 kinase and 4EB-P127. 
Activation of G protein-coupled receptor GPR30 (GPER) by E2 triggered the 
GPER/EGFR/ERK/c-fos signaling pathway, leading to increased VEGF via HIF-1 
upregulation33. Furthermore, ER has been reported to directly induce HIF-1 
transcription, which might modulate the anti-estrogen response in breast cancer 
treatment32. In contrast, ER has been reported to play an opposing role to ER. 
Transcriptional activity of HIF-1 is inhibited by ER, which is mediated by ubiquitin-
dependent degradation of HIF-.  
Despite the numerous studies on HIF-1 regulation by estrogen, the interaction 
between estrogen signaling and HIF-2 regulation is currently unknown. By 
immunohistochemical detection of HIF-2 in tissue microarrays of 282 invasive 
breast cancer cases we previously found that patients expressing high HIF-2 levels 
had a better overall survival rate compared to patients expressing low HIF-2. Our 
study was confirmed by the designation of HIF-2 in a list of genes associated with 
favorable outcome based on studies with different cohorts of breast cancer 
patients34.  
Here, we report a previously not recognized regulation of HIF-2 by estrogen, 
suggesting an inverse interplay between estrogen and HIF-2 signaling, which might 
be involved in breast cancer progression. 
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7.3 Results 
E2 downregulates HIF-2 mRNA and protein levels in ER-positive but not 
ER-negative breast cancer cell lines  
We previously reported a HIF-2 specific regulation of WISP-2 expression in breast 
cancer cells35. Because WISP-2 is a known ER target gene36, we aimed for the 
analysis of the cooperation between estrogen and oxygen signaling. Therefore, the 
time-dependent effect of E2 treatment on HIF signaling in MCF-7 cells was 
investigated. Unexpectedly, HIF-2 mRNA levels were progressively reduced with 
increasing time of E2 treatment (Figure 1A). Maximal inhibitory effects were reached 
after 12 to 24 hours, and the latter time-point was selected for all subsequent 
experiments, also based on our previous observations that HIF-2 protein levels in 
MCF-7 cells are expressed maximally after 24 hours of hypoxic exposure11.  
We further tested the effects of E2 on HIF-2 in additional breast cancer cell lines, 
including another luminal-like ER-positive (T-47D), a basal B-like ER-negative 
(MDA-MB-231), and a basal A-like ER-negative (MDA-MB-468) cell line. Both, HIF-
2 mRNA (Figure 1B) and hypoxically stabilized protein (Figure 1C) levels were 
downregulated in the ER-positive MCF-7 and T-47D but not in the ER-negative 
MDA-MB-231 and MDA-MB-468 cell lines. Exposure to hypoxia (0.2% O2) for 24 
hours generally did not affect the HIF-2 mRNA levels, except in MDA-MB-231 cells 
where HIF-2 mRNA was induced. However, E2 did not alter this cell type-specific 
HIF-2 mRNA regulation. Neither HIF-1 mRNA (Figure 1B) nor hypoxically 
stabilized HIF-1 protein levels (Figure 1C) were significantly affected by 24 hours 
E2 treatment. These data suggest that HIF-2 is specifically downregulated by E2-
ER signaling on the mRNA level which resulted in corresponding changes on the 
protein levels.  
 
The selective estrogen receptor modulator tamoxifen prevents ER-dependent 
HIF-2 downregulation 
To further investigate the involvement of estrogen signaling in HIF-2 and HIF-1 
regulation, MCF-7 cells were treated for 24 hours with the ER-specific agonist 
propyl pyrazole triol (PPT) and a selective agonist for the GPR30 E2 receptor (G-1) 
under normoxic or hypoxic conditions. HIF-2 but not HIF-1 mRNA levels were 
downregulated by PPT but not by G-1 (Figure 2A). Progesterone receptor (PgR) was 
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included as a positive control for ER activation by PPT. These results were 
confirmed in T-47Dcells (Figure 2B).Similar data were obtained on the protein level 
(Figure 2C), suggesting the involvement of ER but not GPR30 in estrogen-mediated 
HIF-2 inhibition.  
The current first line therapy of ER-positive breast cancer patients is the treatment 
with the selective estrogen receptor modulator (SERM) tamoxifen. Therefore, MCF-7 
cells were treated with E2, with or without tamoxifen, under normoxic or hypoxic 
conditions. As shown in Figure 2D, tamoxifen at least partially prevented HIF-2 
mRNA downregulation by E2, while HIF-1 mRNA levels were neither affected by E2 
nor tamoxifen. Vice versa, PgR mRNA upregulation by E2 was partially prevented by 
tamoxifen. As in Figure 1A, hypoxia inhibited PgR induction, probably due to the 
known degradation of ER  protein by hypoxia in MCF-7 cells as shown below37. 
Corroborating the findings on the mRNA levels, tamoxifen also partially prevented the 
E2-mediated downregulation of the hypoxically stabilized HIF-2 protein levels 
(Figure 2E). The slight HIF-2 but not HIF-1 protein downregulation by tamoxifen 
may be explained by the similarly decreased mRNA levels. However, these findings 
suggest that SERMs can reverse the inhibitory effects of estrogen on HIF-2. 
 
Inverse correlation between HIF-2 and ER mRNA levels in breast cancer 
To complement the pharmacological E2 receptor modulation shown above, ER was 
downregulated by siRNA treatment of MCF-7 cells. Knockdown efficiency was 
confirmed by a 96% decrease of the constitutive ER mRNA levels as well as by a 
97% decrease of the E2-induced mRNA levels of the ER target gene PgR (Figure 
3A). Both, basal and E2-inhibited HIF-2 mRNA levels were significantly increased in 
siER but not siCtrl treated MCF-7 cells. While E2 strongly downregulated HIF-2 
mRNA levels in siCtrl cells, the remaining slight downregulation in siER cells was 
not significant (Figure 3A). Similar results were obtained in MCF-7 cells stably 
transfected with three independent shRNA constructs which resulted in 74-83% ER 
knockdown efficiency and in a strong decrease of PgR, whereas constitutive HIF-2 
mRNA levels were enhanced (Figure 3B). Probably due to the remaining ER, 
blockade of the E2-mediated HIF-2 downregulation and PgR upregulation was 
rather inefficient in shER compared with siER cells (data not shown). These 
findings were corroborated on the protein level where hypoxically stabilized HIF-2 
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but not HIF-1 is clearly less downregulated by E2 in siER than in siCtrl treated 
MCF-7 cells (Figure 3C).  
Because the results shown above suggest an inverse correlation between HIF-2 
and ER mRNA levels in breast cancer cell lines, we explored transcriptome data 
from various clinical breast cancer studies employing the R2 microarray analysis and 
visualization platform (http://hgserver1.amc.nl/cgi-bin/r2/main.cgi). A study of 66 
tamoxifen-treated breast cancer patients showed a significant negative correlation 
between the expression of HIF-2 and ER (Figure 3D). Several additional datasets 
from three different microarray studies including 136, 116 and 61 patients, 
respectively, breast cancer patients displayed a similar inverse correlation 
(supplementary Figure 1).  
 
HIF-2 is a positive prognostic factor in HER2-positive breast cancer 
To study the role of HIF-2 in breast tumorigenesis, two tissue microarrays 
containing invasive breast cancer tumor samples derived from 690 breast cancer 
patients with primary breast cancer were immunostained for HIF-2. The tissue 
microarrays contained areas from invasive breast cancer belonging to ER-positive, 
HER2-positive or triple-negative cases, as described previously38. The signals from 
the invasive breast cancer samples in the tissue microarrays were scored based on 
the presence or absence of cytoplasmic and nuclear HIF-2 staining as exemplified 
in Figure 4A. When all 690 cancer cases were included, neither cytoplasmic nor 
nuclear HIF-2 correlated with overall survival (Figure 4B). Stratification of 
cytoplasmic and nuclear HIF-2 to nodal status, tumor stage and histological grade 
showed no correlation with overall survival (supplementary Figures 2A-F). Also the 
analysis of the 82 triple-negative breast tumor samples did not reveal any significant 
association between HIF-2 levels and overall survival (supplementary Figure 2G). 
However, stratification of nuclear HIF-2 according to the HER2 positivity status in 
hormone receptor-positive breast cancer patients displayed a significant direct 
correlation with overall survival (Figure 4C). 
Because the ER-positive breast cancer cell lines used in Figure 1 are not 
overexpressing HER2, we analyzed the hormone receptor and HER2-positive breast 
cancer cell line BT-474. While treatment with 10 nM E2 for 24 hours downregulated 
HIF-2 mRNA levels (Figure 4D), the fold inhibition was less pronounced than in 
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MCF-7 and T-47D cells (Figure 1), and cannot be detected on the protein level 
(Figure 4E). Diminished downregulation of HIF-2 by E2 in HER2-high ER-positive 
BT-474 cells is consistent with the correlation between high HIF-2 levels and better 
survival of hormone receptor and HER2-positive breast cancer patients. 
 
ER-dependent HIF-2 downregulation is independent of mutual HIF 
inhibition  
To address the functional mechanism underlying HIF-2 inhibition by E2/ER, we 
investigated known candidate HIF-2 inhibitors. We and others previously reported 
the mutual inhibition of HIF-1 and HIF-27,39. Because E2 has been shown to 
induce HIF-1 expression33, we hypothesized that increased HIF-1 might 
subsequently decrease HIF-2. This hypothesis was tested by adding E2 to stably 
HIF-1 or HIF-2 depleted MCF-7 cells. As expected, shHIF-1 MCF-7 cells express 
higher levels of HIF-2 mRNA, whereas shHIF-2 had no effect on HIF-1 mRNA 
levels in this cell line (Figure 5A). Both, PgR and ER remained largely unaffected by 
either HIF-1 or HIF-2 knockdown, and E2 downregulated HIF-2 in shHIF-1 to 
the same extent as in shCtrl cells. Also CITED-2, a preferential HIF-2 target gene10,40, 
was still downregulated by E2 in shHIF-1 MCF-7 cells (Figure 5A). Similar results 
were obtained on the protein level (Figure 5B), suggesting that mutual HIF inhibition 
does not play any role in E2/ER-dependent HIF-2 downregulation.  
 
Histone deacetylation is involved in HIF-2 inhibition by E2 
Histone deacetylation is one of the prerequisites for chromatin remodeling and 
regulation of gene expression. In order to study the role of histone deacetylation in 
HIF-2 transcriptional regulation, MCF-7 cells were treated with E2 in the absence or 
presence of the class I and II mammalian histone deacetylase (HDAC) inhibitor 
trichostatin A (TSA). While TSA alone had no effect, it prevented HIF-2 mRNA 
(Figure 6A) and protein (Figure 6B) downregulation by E2, suggesting that HDACs 
are involved in HIF-2 regulation by E2. 
According to published chromatin immunoprecipitation-sequencing (ChIP-seq) 
data17, ER binds to four distinct regions within the first intron of the gene encoding 
HIF-2 (EPAS1) upon E2 treatment (supplementary Figure 3A). In silico analysis 
revealed that these regions contained conserved estrogen response element (ERE) 
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binding motifs. All four regions displayed robust DNaseI hypersensitivity (reflecting 
open chromatin) and the methylated and acetylated histone marks H3K4Me1 and 
H3K27Ac, respectively (reflecting active enhancers), but not H3K4Me3 (reflecting 
active promoters) in MCF-7 cells (supplementary Figure 3B). Based on ChIP-seq 
information deposited in the UCSC-integrated ENCODE database, ERE4 also 
displayed binding of ER in T-47D breast cancer cells. Interestingly, transcription 
factor (TF) ChIP-seq data further revealed the binding of GATA-2 and GATA-3, 
established transcriptional repressors41-44, at ERE3 and ERE4 (supplementary Figure 
3B). Moreover, ER also binds to an ERE within the HIF1A gene, overlapping with 
GATA-3 binding (data not shown).  
To analyze the involvement of ERE 1 to 4 in E2 regulation of EPAS1 gene 
expression, we evaluated their potential to regulate SV40 promoter-driven firefly 
luciferase reporter gene expression. The reporter gene constructs were transiently 
transfected into MDA-MB-231 cells together with an ER overexpression vector. 
Transfected cells were treated with E2 for 24 hours under normoxic or hypoxic 
conditions and the luciferase activities determined. While ERE1 and ERE2 had no 
effects, ERE3 and ERE4 significantly enhanced E2-induced reporter gene activity 
(Figure 6C).  
Plasmids containing ERE3 and ERE4 were then transfected into MCF-7 cells with or 
without ER, GATA-2 or GATA-3. Whereas co-transfection of the reporter genes 
together with GATA overexpression vector alone did not result in the activation of 
luciferase activities upon E2 treatment, co-overexpression of ER resulted in 
significant E2-dependent activation of luciferase activity (Figure 6D). Taken together, 
these results indicate that E2-activated ER locates to at least one ERE within the 
EPAS1 gene and recruits several transcriptional co-factors, including GATA factors 
and HDACs, leading to transcriptional repression of the EPAS1 gene. 
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7.4 Discussion 
Cross-talk between estrogen signaling and hypoxia-dependent signaling pathways 
has previously been reported, focussing on the interactions between estrogen 
signaling and HIF-1 regulation27,32,37,45,46. In the present study, we report for the first 
time the association between estrogen signaling and HIF-2 regulation. Estrogen 
signaling is an essential component of breast cancer progression as indicated by the 
prevalence of ER overexpression in breast cancer patients47. Hypoxia represents 
another major factor in breast cancer progression, and the interaction between these 
two signaling pathways hence is of major clinical importance4.  
In this study, we observed an ER-dependent downregulation of HIF-2 mRNA 
levels by E2. Cell lines with different ER status, pharmacological and RNA 
interference experiments confirmed the requirement of ER for the E2 effects on 
HIF-2. Higher constitutive expression of HIF-2 both on the mRNA and protein 
levels in ER depleted MCF-7 was phenocopied in microarray data of breast cancer 
patients with different ER levels. This observation suggests a constitutive ER-
dependent suppression of HIF-2 expression, which is strengthened by hormonal 
ER activation. Of note, the E2-induced HIF-2 repression was almost completely 
abrogated in hormone receptor and HER2 triple-positive cells. While it is currently 
unclear how HER2 interferes with HIF-2 regulation, HER2 signalling is known to 
induce HIF-1 by PI3K/Akt/mTOR signalling48-50, and a similar mechanism might also 
overcome E2-mediated HIF-2 repression. 
The ER utilizes multiple mechanisms to either induce or suppress transcription of its 
target genes, which include direct binding of ligand-activated receptor to the DNA at 
the EREs, followed by recruitment of transcriptional co-regulators51,52. Also an 
indirect modulation via sequestration of general transcriptional components has been 
suggested53. ER activation is usually assumed to be associated with increased 
gene expression, however in fact almost 70% of the genes regulated by E2 are 
down-regulated in MCF-754. Our observation of HIF-2 down-regulation by E2 is thus 
consistent with the majority of genes being downregulated upon E2 treatment of 
MCF-7 cells.  
Currently, we have no definitive explanation for the mechanism by which ER inhibits 
HIF-2. The state of histone acetylation is a good predictor of gene activity, and 
HDACs are known to repress gene expression by modulating the conformational 
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state of the chromatin. Furthermore, HDACs have been reported to be involved in 
tumorigenesis55,56. Estrogen-mediated repression of the cell cycle inhibitor Reprimo 
(RPRM) required the interactions between ER, HDAC7 and FoxA157. In addition, 
expression of the gene encoding human uridine diphosphate glucuronosyltransferase 
(UGT1A) was inhibited in the presence of ER. ChIP assays further demonstrated 
the recruitment of ER, HDAC1 and HDAC2 to the xenobiotic response elements of 
UGT1A promoters during gene repression58. Moreover, tamoxifen-bound ER has 
been reported to recruit HDAC to silence gene transcription of ER targets59. 
Interestingly, tamoxifen treatment of MCF-7 cells has recently been shown to 
significantly increase HDAC1 binding on the ERE of HIF-132. In our study, treatment 
of MCF-7 cells with E2 and TSA abolished ER-dependent HIF-2 regulation. We 
identified several EREs within the regulatory region of the EPAS1 gene, and ERE4 
interacts with ER in both MCF-7 and T-47D cells. ERE4 can also interact with 
GATA-2 and GATA-3, consistent with recent studies revealing substantial enrichment 
of GATA3 binding to ER occupied DNA regions60,61. Furthermore, besides inducing 
gene expression, GATAs have been reported to also exert repressive functions41-44. 
Luciferase reporter gene assays demonstrated a functional interaction between 
GATA-2/3 and the EPAS1 ERE4, suggesting a role of ERE4 in ER-dependent HIF-
2regulation. 
In conclusion, hormone activation may lead to ER dimerization, binding to EPAS1 
ERE4, recruitment of transcriptional co-factors, including GATAs and HDACs, and 
repression of gene expression. The lack of ER in triple-negative breast cancer 
allows for constitutively higher HIF-2 and prevents estrogen-mediated HIF-2 
downregulation seen in ER positive breast cancer. Specifically in triple-positive 
HER2 overexpressing breast cancer, the downregulation of HIF-2upon E2 
treatment was less pronounced on the mRNA level and was absent on the protein 
level, which might partially explain the correlation with prolonged overall survival. 
 
  
Chapter 7: Manuscript II. Submitted to Oncotarget 
85 
 
7.5 Material and Methods 
Reagents 
E2 (17-estradiol), PPT (propyl pyrazole triol), tamoxifen and fulvestrant were 
purchased from Sigma-Aldrich (St Louis, MO, USA). G-1 was purchased from Tocris 
Biosciene (Bristol, UK). Reagents were dissolved in ethanol or DMSO. Antibodies 
against the following proteins were used: HIF-1 (BD Transduction Laboratories, 
Allschwil, Switzerland), HIF-2 (immunoblotting: Abnova Corporation, Taiwan; 
immunohistochemistry: Abcam, Cambridge, UK), ER (Santa Cruz Biotechnology, 
Dallas, TX, USA), and -actin (Sigma-Aldrich). 
Cell culture and treatments  
The human breast cancer cell lines MCF-7, T-47D, MDA-MB-231, MDA-MB-468 and 
BT-474 were cultured in high-glucose Dulbecco’s Modified Eagle’s Medium (Sigma-
Aldrich). Before experiments, the cells were maintained in phenol red-free DMEM 
supplemented with 10% charcoal-treated FCS (Gibco, Thermo Fischer Scientific, 
Waltham, MA, USA) for 1 to 2 days. Cells were treated with E2 or vehicle control 
(0.1% ethanol or 0.1% DMSO) alone or in combination with other ligands for 24 hours 
under normoxic and hypoxic conditions. Hypoxic experiments were performed at 
0.2% oxygen and 5% CO2 in a gas-controlled glove box (Invivo2 400, Baker Ruskinn, 
Bridgend, UK) as described previously62.  
mRNA and protein detection 
Total cellular RNA was extracted as previously described. Total RNA (2 g) was 
reverse transcribed (RT) using AffinityScript reverse transcriptase (Agilent, Santa 
Clara, CA, USA) and complementary DNA (cDNA) levels were estimated by 
quantitative polymerase chain reaction (qPCR) using the primers listed in 
supplementary Table 1 and a SYBR® Green qPCR reagent kit (Sigma-Aldrich) in a 
MX3000P light cycler (Agilent). Transcript levels were calculated by comparison with 
a calibrated standard and expressed as ratios relative to ribosomal protein L28 
mRNA levels. Immunoblotting and breast cancer tissue microarray analysis were 
performed as previously described35,38.  
Plasmid construction and reporter gene assays 
DNA fragments containing the EPAS1-derived EREs were generated by PCR using 
the primers listed in supplementary Table S1, and cloned into the pGL3-promoter 
luciferase reporter vector (Promega Corporation, Madison, WI, USA). A cDNA 
encoding human ER cloned into the pCMV5 mammalian expression vector was 
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kindly provided by A. Odermatt (Basel, Switzerland). Human GATA-2, GATA-3, and 
GATA-4 cloned into pcDNA3.1 were kindly provided by C. Dame (Berlin, Germany). 
Dual luciferase reporter gene assays were performed as described previously63.  
Statistical analysis 
If not indicated otherwise, unpaired Student’s t-tests were applied. Differences 
between two values at the P<0.05 level were considered to be statistically significant.  
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7.7 Figures 
 
 
Figure 1: HIF-2 regulation by estrogen in breast cancer cell lines. A. MCF-7 cells were treated 
with 10 nM E2 for the indicated time periods. HIF-2 mRNA levels were quantified by RT-qPCR, 
corrected for the endogenous L28 mRNA levels and normalized to the starting time point. B. ER-
positive (MCF-7 and T-47D) and ER-negative (MDA-MB-231 and MDA-MB-468) breast cancer cell 
lines were treated with 10 nM E2 for 24 hours under normoxic or hypoxic conditions. HIF-2 mRNA 
levels were quantified as above. Shown are mean values ± standard errors of the mean (SEM) of 
three to four independent experiments. For statistical evaluation, the effects of E2 treatment were 
compared with the control (Ctrl) treatment. *P<0.05; **P<0.01; ***P<0.001. C. HIF-2 protein was 
detected by immunoblotting and constitutively expressed -actin was used as loading and blotting 
control.  
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Figure 2: ER-mediated regulation of HIF-2 by estrogen. MCF-7 (A and C) or T-47D (B) cells 
were treated for 24 hours with 10 nM PPT, an ER-specific agonist with approx. 400 times higher 
affinity towards ER than towards ER, or 1 M G1 (MCF-7 only), a GPER-specific agonist, under 
normoxic or hypoxic conditions. The mRNA (A and B) and protein (C) levels were determined by RT-
qPCR and immunoblotting, respectively. E. and D. Tamoxifen (5 M) was added to MCF-7 cells with 
or without 10 nM E2 and mRNA (D) and protein (E) levels were determined. Shown are mean mRNA 
values ± SEM of three independent experiments. For statistical evaluation, the effects of E2 treatment 
were compared with control (Ctrl) treatment. *P<0.05; ***P<0.001.  
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Figure 3: Reciprocal regulation of HIF-2 and ER. ER was knocked down in MCF-7 cells using 
siER (A and C) or shER (B) and then treated with 10 nM E2 under normoxic or hypoxic conditions. 
mRNA (A and B) and protein (C) levels were subsequently determined by RT-qPCR and 
immunoblotting, respectively. Shown are mean mRNA values ± SEM of three independent 
experiments. For statistical evaluation, the effects of ER silencing were compared with siCtrl cells; 
the effects of E2 treatment were compared with control (Ctrl) treatment. *P<0.05; **P<0.01. D. 
Microarray data from public databases were compiled using the R2 genomic analysis tool. 
Significance of the negative correlation between HIF-2 (red dots) and ER (blue squares) mRNA 
levels was assessed by one-way ANOVA.  
 
 
 
 
 
 
 
 
 
 
 
Chapter 7: Manuscript II. Submitted to Oncotarget 
95 
 
 
 
Figure 4: HIF-2 as a prognostic factor in HER2-positive breast cancer. A. Scoring system and 
representative images for cytoplasmic and nuclear HIF-2 staining of invasive breast cancer tissues. 
B. HIF-2 was scored in tissue microarrays of 608 invasive breast cancer cases (excluding triple-
negative cases) and displayed in Kaplan-Meier survival curves. C. Survival curves of hormone 
receptor-positive and HER2 overexpressing breast cancer patients according to HIF-2 scores. D. and 
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E. Triple-negative BT-474 breast cancer cells were treated with 10 nM E2 for 24 hours under normoxic 
or hypoxic conditions, and mRNA (D) and protein (E) levels of HIF-2 were determined. Shown are 
mean mRNA values ± SEM of three independent experiments. For statistical evaluation, the effects of 
E2 treatment were compared with control (Ctrl) treatment. *P<0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 7: Manuscript II. Submitted to Oncotarget 
97 
 
 
 
Figure 5: Mutual HIF- inhibition is not involved in E2-dependent HIF-2 regulation. A. MCF-7 
shCtrl, shHIF-1 and shHIF-2 cells were treated with 10 nM E2 for 24 hours under hypoxic 
conditions and mRNA levels determined by RT-qPCR. Shown are mean values ± SEM of three 
independent experiments. For statistical evaluation, the effects of E2 treatment were compared with 
control (Ctrl) treatment. B. Immunoblotting of MCF-7 cells treated with E2 as above.  
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Figure 6: Role of histone deacetylation in E2-dependent HIF-2 regulation. MCF-7 cells were 
treated with 10 nM E2 with or without 250 nM trichostatin A (TSA), an inhibitor of HDAC. mRNA (A) 
and protein (B) levels were determined by RT-qPCR and immunoblotting, respectively. C. Dual 
luciferase reporter gene assays were performed with MDA-MB-231 cells transiently co-transfected 
with a constitutively expressed Renilla luciferase plasmid, an EPAS1-derived ERE1 to 4 driven firefly 
reporter gene plasmid, and an ER overexpression vector. D. Luciferase reporter gene assays were 
performed with MCF-7 cells transiently co-transfected with a constitutively expressed Renilla luciferase 
plasmid, an EPAS1-derived ERE3 or ERE4 driven firefly luciferase reporter gene plasmids, and 
expression vectors for ER, GATA-2 or GATA-3. Shown are mean values ± SEM of three independent 
experiments. For statistical evaluation, the effects of E2 without or with TSA treatment (A) were 
compared with control (Ctrl) treatment; the effects of E2 and TSA treatment were compared with E2 
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treatment. For dual-luciferase reporter gene assays (C and D), three independent experiments were 
performed in triplicates. The relative luciferase activity was obtained by dividing the firefly luciferase 
values by the corresponding Renilla luciferase values. *P<0.05; **P<0.01; ***P<0.001.  
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Figure S1: Negative association between ERa and HIF-2a in breast cancer. Microarray data from 
three independent studies were compiled using the R2 genomic analysis tool. HIF-2a mRNA levels 
negatively correlate with ERa levels in breast cancers in all studies analysed, as assessed by one-way 
ANOVA. 
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Figure S2: Kaplan-Meier survival curves related to HIF-2a scores. Kaplan-Meier survival curves of 
cytoplasmic (A, B, E and G) and nuclear (C, D, F and G) HIF-2a scores in breast cancer samples 
stratified according to nodal status (A and C), tumour stage (B and D), histological grade (E and F), or 
in triple-negative breast cancer (G).  
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Figure S3: Potential ERE sites in EPAS1 gene. A. Schematic representation of the EPAS1 gene, 
indicating four estrogen response elements (EREs) located within the first intron. B. UCSC-integrated 
ENCODE data of the four ERE-containing loci (ERE1-4) of the EPAS1 gene.
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8. Discussion and final remarks 
Breast cancer is one of the most common cancers and affects millions of women 
each year1,2. As a multifactorial disease, various factors influence the risk of breast 
cancer (Table 8.1)9. Molecularly, the involvement of both hypoxia and estrogen 
signalling pathways in the development and progression of breast cancer has been 
well established. 
Table 8.1 Factors influencing breast cancer risk (adapted from 9). 
Factors that influence breast cancer risk 
Genetic susceptibility and family history 
Endogenous steroid hormone levels and exogenous hormone  
Age at menarche and age and type of menopause 
Parity and lactation 
Life style, such as alcohol consumption and level of physical activity 
Height, weight and body size 
 
Among the HIF- isoforms, HIF-1 is the more thoroughly investigated. Although 
HIF-2 has been long reported, there are still gaps regarding our understanding of 
the functions and regulations of HIF-2in breast cancer. Therefore I aimed for the 
investigation of both the functions and modulations of HIF-2 by utilising breast 
cancer cell lines. Specifically, I aimed to: 
1. Elucidate the regulation of WISP-2 by HIF-2 to reveal the role of HIF-2 in 
breast tumourigenesis. Furthermore, I aimed to explore the possible 
contributions of both HIF-2 and WISP-2 in the aggressiveness of breast 
cancer, and hence their contribution in overall survival in breast cancer 
patients. 
2. Study the potential regulation of HIF-2 by estrogen signalling in ER-positive 
breast cancer cell lines. 
 
8.1 HIF-2-dependent regulation of WISP-2 and its effects on breast 
cancer progression  
Immunohistochemical detection of HIF-2, amphiregulin (AREG) and WISP-2 in 
tissue microarrays of 282 breast cancer patients with primary mammary carcinoma 
confirmed the higher abundance of AREG and WISP-2 in tumours associated with 
positive HIF-2161. Furthermore, Kaplan-Meier survival curves revealed a significant 
survival benefit of patient subgroups expressing both AREG and WISP-2 at high 
levels161. Buoyed by the clinical evidence for a relation between HIF-2 and WISP-2, 
I decided to investigate further the molecular mechanism behind the regulation of 
WISP-2 by HIF-2 and the functional consequences of hypoxic WISP-2 regulation in 
breast cancer progression. Four hypoxia response elements (HREs) were discovered 
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within the WISP-2 promoter region, in which two HREs were functional and were 
required for HIF-2α-dependent regulation of WISP-2 promoter activity in MCF-7. 
Furthermore, the two active HREs are located within a microsatellite (MS) region 
which is highly polymorphic and has been established to play an essential role in 
tumour progression.   
WISP-2 has been reported previously to correlate inversely with the aggressiveness 
of breast, pancreatic, colon and gastric cancer171,173,293,294. In breast cancer, WISP-2 
shows transient overexpression during the progression of breast cancer; while it is 
not expressed in normal human mammary epithelial cells (HMECs), it is highly 
expressed in ER-positive non-invasive breast cancer cell lines, and is again 
undetected in triple-negative highly invasive breast cancer cell lines. The 
observations suggest the potential roles of WISP-2 as a tumour suppressor-like 
factor. Another prognostic marker for the progression of breast cancer is tumour 
macrophage infiltration. Immunohistochemical staining of 300 breast cancer samples 
with macrophage markers, CD68 and CD163, and pan-leukocyte marker CD45 was 
performed. Consistent with the higher survival benefit of WISP-2 expression in breast 
cancer patients, a negative correlation between WISP-2 and tumour macrophage 
numbers were observed, suggesting that HIF-2-dependent expression of WISP-2 is 
a marker for better prognosis, due to the lower counts of macrophage infiltration and 
lower cancer aggressiveness. 
Finally, in order to investigate the functional consequences of HIF-2-dependent 
regulation of WISP-2, WISP-2 was knocked down (KD) in non-invasive MCF-7 cells 
and exposed to normoxia and hypoxia for different experimental settings. 
Proliferation of WISP-2-KD MCF-7 cells, but not HIF-2-KD MCF-7 cells was 
significantly reduced under normoxia and hypoxia. Furthermore, the capability of HIF-
2-KD and WISP-2-KD MCF-7 cells to form colonies independently of anchorage 
was increased compared to control MCF-7 cells. Likewise, knockdown of both HIF-
2 and WISP-2 resulted in a significant increase in the recovery of the scratch 
through a confluent cell layer. Interestingly both the anchorage-independent colony 
formation and scratch recovery of HIF-2 and WISP-2 knockdown were slightly 
reduced under hypoxia, which might be due to the residual WISP-2 induction under 
hypoxia. Together, these observations are consistent with a role of HIF-2-
dependent regulation of WISP-2 in cancer progression.   
 
8.2 Estrogen-dependent regulation of HIF-2 in breast cancer 
In breast cancer, cross-talk between hypoxia and estrogen signalling has been 
previously reported232,233,237. E2 treatment of ER-positive MCF-7 cells by our 
laboratory at different time-points resulted in the progressive down-regulation of HIF-
2 mRNA levels under normoxia. To investigate the requirement for ER in the 
downregulation of HIF-2, two luminal-like ER-positive (MCF-7, T-47D), one basal A-
like triple-negative (MDA-MB-468), and one basal B-like triple-negative (MDA-MB-
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231) breast cancer cell line were treated with E2, and HIF-2 mRNA and protein 
levels were investigated. Consistent with our hypothesis that the downregulation of 
HIF-2 by E2 is ER-dependent, HIF-2 mRNA and protein levels were 
downregulated upon treatment with E2 in ER-positive cell lines and the 
downregulation is completely absent in triple negative cell lines. Subsequent 
treatments of MCF-7 cells with ER-specific (PPT) and GPR30-specific (G1) 
agonists further confirmed the role of ER in HIF-2 downregulation. 
To examine the clinical relevance of ER-dependent HIF-2 regulation, tamoxifen is 
used to antagonise the effect of E2 on MCF-7 cells. Tamoxifen, a selective estrogen 
receptor modulator (SERM) is currently used as an adjuvant to chemotherapy on ER-
positive breast cancer patients. Due to its extraordinary efficacy against breast 
cancer mortality, it is currently recommended by the World Health Organisation 
(WHO) as the treatment of choice for estrogen-sensitive breast cancer. In our 
laboratory, treatment of E2 in the presence of tamoxifen results in diminished HIF-2 
downregulation, giving a hint about the clinical importance of ER-dependent HIF-2 
regulation in breast cancer progression. It would be fascinating to look at the 
changes in the level of HIF-2 in samples from breast cancer patients. Unfortunately, 
we cannot compare between the experimental protocol we used for our treatment of 
breast cancer cell lines and the current treatment protocol on breast cancer patients. 
In our treatment protocol, we treated MCF-7 cells with E2 with or without tamoxifen 
before quantifying the changes in mRNA and protein levels. However, in a clinical 
setting, once a patient is diagnosed with breast cancer, a surgery was performed to 
remove the tumour. After the ER-status of the breast cancer has been established, 
then treatment either with or without tamoxifen can proceed. As such, it is not 
possible for us to compare the two different experimental settings and hence our lack 
of data in confirming our in vitro observations.  
Interestingly, when ER was knocked-down in MCF-7, HIF-2 mRNA levels 
increased significantly, further indicating the modulation of HIF-2 transcription by 
ER even in the absence of E2. Similarly, an increase in HIF-2 mRNA and protein 
levels can be observed even though this was not statistically significant. Analysis of 
gene microarray data from various breast cancer studies showed similar inverse 
correlation between the mRNA levels of HIF-2 and ER in breast cancer patients as 
we found in our cell line study. To elaborate the clinical relevance of this modulation, 
samples from breast cancer patients were investigated based on the ER and HIF-
2 protein levels against the survival of the patients. Additionally, samples were 
stratified based on ER and HER2 expression, nodal status, tumour stage, and 
histological grade. Differing from our previous report, no significant survival benefit 
was observed in breast cancer patients expressing higher levels of HIF-2The 
previous study used 282 samples from patients with primary mammary carcinoma 
without further stratification of the samples into different categories of breast cancer. 
In the current study, 690 breast cancer patients with primary mammary carcinoma 
were used. In addition, the samples were mixed population and were classified into 
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ER-positive, ER-positive HER-2-positive, and triple-negative breast cancers. As such, 
the latter study included more information and provided better statistical power for our 
calculation at the survival benefit. In fact, stratification of HIF-2 nuclear expression 
according to HER2 status of patients displayed a significant survival benefit for ER 
and HER-2-positive patients. Intriguingly, treatment of E2 on BT474, a triple-positive 
breast cancer cell line, showed less downregulation of HIF-2 compared to treatment 
of ER-positive breast cancer cells, in line with a role of HIF-2 as gene associated 
with favourable prognosis.  
Mechanistically, mutual HIF inhibition is not responsible for the regulation of HIF-2 
by ER. Results from this study suggest a transcriptional modulation of HIF-2 by 
ER in the presence and absence of E2. One of the means of gene regulation is by 
chromatin remodelling, in which histone deacetylation is one potential mechanism. 
Inhibition of HDACs prevented the downregulation of HIF-2 by E2, indicating the 
role of histone deacetylation in the observed modulation of HIF-2. Moreover, 
dysregulation of HDACs had been reported in numerous cancer cases, including in 
breast cancer. To further explore the potential mechanism, EPAS1 was screened for 
the presence of EREs. Four EREs were discovered within the first introns of EPAS1, 
in which two EREs; ERE3 and ERE4 were found to be active, particularly in the 
presence of GATA-2 and GATA-3. Activation of ER by E2 results in the 
translocation of the receptors into the nucleus, where the E2-ER dimer complex 
recruits co-regulators, which include possibly GATA-2, GATA-3 and HDACs. Histone 
deacetylation due to the recruited HDACs causes the remodelling of chromatin and 
subsequently repression of HIF-2 transcription. Further studies are warranted for 
the elaboration of the mechanism behind HIF-2 regulation.  
One question that arose from this study is which type of HDAC is involved in the 
deacetylation of EPAS1. HDACs can be classified into three classical classes (I, II, 
and IV) and consist of total 11 members. Another class of HDACs, class III or sirtuins 
are unique due the possession of NAD-dependent catalytic sites and resistant to 
HDAC inhibitors. HDACs have been reported to be involved in 
tumourigenesis284,285,295. Class I HDACs: HDAC-1, -2, and -3 are especially often 
overexpressed in human tumours, including breast tumours, and knockdown of 
HDAC-1 and -2 has been shown to be sufficient to reduce tumour growth in 
vivo285,296,297. It will be interesting to distinguish which HDAC is involved in HIF-2 
downregulation and if the implicated HDAC is also linked to breast cancer 
progression. One prime candidate HDAC is HDAC7. Previously, it has been reported 
that estrogen repression of RPRM (repression of reprimo), a cell cycle inhibitor, 
requires interaction between ER, HDAC7 and FoxA1286. HDAC7, a class II HDAC, 
binds to ER and represses ER’s transcriptional activity without deacetylation286. 
Additionally, class II HDACs have been shown to regulate transcription by interacting 
with a complex containing HDAC3 and the transcriptional corepressor NCoR/SMRT, 
providing another possible way in which ERα activation represses transcription of 
HIF-2295. Pharmacological approaches to inhibit class II HDAC are limited due to 
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the fact that currently no class II-specific HDAC inhibitor exists. One possible 
approach is to specifically knockdown members of class II HDAC to identify the 
HDACs involved in HIF-2 regulation.   
Another question is the role of GATA-2 and GATA-3 in the regulation of HIF-2. 
ERE4 has been identified using UCSC genome browser to be bound by ER in both 
MCF-7 and T-47D195. Furthermore, from the same genome browser, ERE4 is also 
the site of binding for GATA-2 and GATA-3. As such, ERE4 is assumed to be the 
primary target of ER binding upon treatment with E2. Indeed, luciferase reporter 
assays showed induction of activity upon treatment with E2 in the presence of both 
ER and GATA-2 or GATA-3. However, this did not explain the downregulation of 
HIF-2 mRNA levels and protein levels. One explanation is the artificial setting of the 
assay, in which a short string of DNA containing ERE4 was expressed together with 
ER and GATA-2/3. It is now well established that gene regulation is a dynamic 
event, involving multiple factors and looping of downstream or upstream DNA. 
Whereas luciferase reporter assays represent a powerful tool to study gene 
regulation, expression of a non-chromatinised DNA region only containing ERE4 
does not fully reflect in vivo regulation of EPAS1. Our results however prove the 
functionality of ERE4 in regards to ER, GATA-2 and GATA-3 binding. To circumvent 
the limitation of luciferase reporter assays, GATA-2 or GATA-3 could be knocked 
down in ER-deficient MCF-7, followed by treatment with E2. In the absence of ER 
and GATA-2/3, it is expected that HIF-2 levels will increase and the downregulation 
in the presence of E2 will be blunted. Moreover, the CRISPR-Cas method can be 
used to mutate the ERE4 within EPAS1 followed by treatment with E2. Destruction of 
ERE4 within EPAS1 will result in complete exclusion of ER binding upon E2 
activation, and hence elimination of HIF-2 regulation. 
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8.3 Final remarks 
Separately, hypoxia and estrogen play important role in breast cancer development. 
Unsurprisingly, the two distinct signalling pathways might cross-path and affect each 
other. In this thesis, I have studied both the functional consequences and regulation 
of HIF-2 in breast cancer. The results from the study of the effects of estrogen-
dependent regulation of HIF-2 prompted me to propose a potential mechanism 
behind the observed modulation (Figure 8.1). 
 
Figure 8.1 The proposed model for the E2-dependent HIF-2a regulation. Activation of ERa by E2 
results in translocation of the activated ERa homodimer to the nucleus. Once in the nucleus, the 
activated receptors recruit co-regulators, including GATA-2/3 and HDAC, which subsequently 
deacetylate the down-stream target gene (EPAS1) and repress the transcription of the target gene. 
In summary, my thesis reports a novel regulation of HIF-2 by estrogen signalling, 
which might partially explain the association of high HIF-2 in HER2-breast cancer 
patients with better prognosis. The importance of both estrogen signalling and HIF-
2 in breast cancer development suggests the possibility of HIF-2 levels and ER 
status as prognostic markers in breast cancer. Furthermore stabilisation of HIF-2 or 
maintenance of HIF-2 levels might be a treatment option for ER-positive breast 
cancer patients.  
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